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1. Introduction  
An individual receiving the diagnosis of rheumatoid arthritis (RA) will immediately have 
several years deducted from her or his statistical life expectancy. The mortality rate in 
patients with RA is 1.5-1.6 compared to that of the general public, and cardiovascular 
disease (CVD) accounts for 40-50% of the deaths [2,3]. Many of us will die from a CVD, 
but in people with RA, death often occurs at an earlier age.  
Patients with RA may well have an unfavourable risk profile already at their first 
visit to the rheumatologist’s office. The patient with RA has been shown to be at a 
considerably increased risk of developing a myocardial infarction (MI) already in the two 
years prior to fulfilling the American Congress of Rheumatoloy (ACR) diagnostic criteria 
for RA [4]. The patients with RA may have an unfavourable genetic profile, and there is 
evidence that they are more likely to have a close relative who has suffered from a 
myocardial infarction before the age of 60 [5]. Indeed the human leukocyte antigen (HLA) 
shared epitopes (SE) have been shown to be significant predictors of ischaemic heart disease 
(IHD) while also being associated with greater RA susceptibility and severity [6]. Common 
risk factors for CVD and RA such as smoking, or lack of physical exercise which is a 
consequence of RA and a risk factor for CVD, may also be of importance [5]. 
If we are to prevent cardiovascular events in patients with RA we must know which 
patients to focus our efforts on, and specifically which RA disease characteristics signal an 
increased risk of CVD. Biomarkers play an important role as predictors enabling us to audit 
the individual before the clinical disease becomes apparent. This thesis endeavours to make 
a small contribution in a rapidly expanding field and stands at the cross-road between 
cardiovascular medicine and rheumatology. 
The transition from internal medicine to the field of rheumatology spurred my 
personal motivation for this work. As several authors drew my attention to the 
immunological similarities between the atherosclerotic lesion and synovitis, I hoped to find 
a PhD project that would allow me to develop my interest in both fields. The impetus to 
submerge myself in a PhD project came from listening to colleagues talk so animatedly 
about their fields of interest. The saying “The devil is in the details” sprung to my mind 
while considering project organizations and thesis work. However, I also had a little hope 
that there might be some truth behind the alternative idiom “God is in the details” (Ludwig 
Mies van der Rohe 1886-1969). 
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2. Background  
2.1 Rheumatoid arthritis 
2.1.1 Definition  
RA is classified as a chronic, systemic, autoimmune disease. The major finding is a 
symmetrical swelling of the joints, predominantly affecting the wrists, metocarpophalangeal 
and proximal interphalangeal joints in the hands, and the metatarsophalangeal joints of the 
feet [7]. The classical symptoms are inflammatory joint pain and morning stiffness lasting 
more than one hour. The disease has the potential to become systemic causing constitutional 
symptoms such as shortness of breath due to pulmonary fibrosis or pericarditis, dry eyes and 
mouth due to secondary Sjøgren´s syndrome [8], and subcutaneous nodules. The 1987 ACR 
criteria has until very recently been used in order to classify patients. For the diagnosis of 
RA a patient must fulfil 4 out of 7 criterions; morning stiffness  1 hour, arthritis of  3 
joint areas, arthritis of hand/wrist joints, symmetrical arthritis, rheumatic nodules, serum 
rheumatoid factor (RF) and radiographic changes [9].  
2.1.2 Epidemiology 
The incidence rate of RA in Oslo has been estimated across six consecutive inception 
cohorts, with an average of 25.7 cases in 100 000 patient years. Of the patients identified, 
74.4% were female, and 25.6 % male [10]. The highest incidence rates were found in the 
oldest age groups (60-79) for both sexes (average of 60 cases pr 100 000 patient years). The 
overall prevalence of RA in Oslo in adults aged 20-79 has been estimated to be 0.44%, 
although women over 60 years have a prevalence that is at least three-fold this value [11]. 
Studies from the Norfolk Health Authority show similar findings with a female incidence 
rate of 36/100 000 and male incidence rate of 14/100 000. The peak onset was also in this 
study found to be in women aged 65-74, although the female: male ratio was attenuated 
with increasing age [12]. The prevalence of RA in the Norfolk cohort was however almost 
twice that in the Norwegian cohorts and studies from North America and Greece have also 
found a higher prevalence [12,13].  Meta-analyses of several epidemiological studies have 
indeed reported on divergent incidence and prevalence rates across geographical locations 
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and sampling dates, but despite differences there seems to be increasing support for the 
concept of a declining incidence of RA with a shift towards delayed disease onset  
[12-15]. 
2.1.3 Pathogenesis 
The pathology of RA starts prior to clinical disease in many patients. Anti- cyclic 
citrullinated peptide antibodies (anti-CCP) can be detected many years preceding the onset 
of the disease, and assign a near 70% risk of developing the disease in patients who have a 
strong family history of RA [16-18]. Genetic risk factors such as the SE alleles interact with 
smoking, and probably other environmental factors, to increase the risk of developing anti-
CCP antibodies [19]. Auto-antibodies towards IgG, termed the RF and until recently 
considered the most important serological biomarker of RA, are now rather explained as bi-
products of inflammatory activity, whereas anti-CCP antibodies may be more specific for 
RA [20]. Although the immunity towards citrullinated peptides are thought to contribute 
towards the development of RA resulting in a distinct subset of anti-CCP positive RA 
patients, details of the aetiology triggering citrullination are still missing [20,21]. 
Synovial inflammation is the hallmark of RA and this process is perpetuated by 
activated B and T cells interacting with macrophage mediated cytokine release [21]. 
Tumour necrosis factor alpha (TNF-α) is considered a key player in cartilage destruction 
and bone resorption [22]. TNF-α is also responsible for the activation of endothelial cells 
and of other cytokines such as IL-1 and IL-6. 
2.1.4 Disease course  
RA is described as a progressive disease and without treatment it will cause joint 
destruction, pain and disability in the majority of patients [7]. A study from 1984 published 
data on the disease progression of 75 patients who had initially been referred to the clinic 
for intra-articular corticosteroid injections. At inclusion the mean age (range) was 54.7 (27-
79) years, and the disease duration was 11.2 years. After 9 years, 20 patients had died and 
there was evidence of a significantly reduced functional capacity in the survivors. Of the 
patients who were of such age as to be eligible for work both in 1973 and 1982, 41% were 
working at inclusion and only 15% after 9 years [23]. Although dated, this study is still 
relevant today as it describes the course of RA, prior to the use of MTX and modern 
biologic agents. Data from the ORAR also published prior to the dawn of TNF-  inhibitor 
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use in Norway, have similarly concluded that at least 40% of newly diagnosed patients had 
clinically important changes in health status after 5 years [10].  
General mortality rates are increased in patients with RA and a recent meta-analyses has 
reviewed the available literature [2]. Sokka et al. identified 84 cohorts, after excluding serial 
publications on the same data set. The median standardized mortality ratio (SMR) was 1.57, 
ranging from 1.62 in the older cohorts, and 1.54 in the most recent studies. The SMR was 
slightly lower in inception cohorts, with a median value of 1.28 [2].  CVD was the most 
frequent cause of death, whereas infections were most increased relative to the general 
population. Cancers in general were not increased, whereas lymphomas were more frequent 
in patients with RA.   
2.1.5 Treatment of RA 
The Norwegian pharmacological practice in treating patients with RA has been documented 
in 1300 patients treated between 1980 and 1993 [24].  This study  found that the median 
time to start of treatment from disease onset was  3.1 years, and reported on a steep increase 
in the use of MTX during the study-period [24]. The introduction of MTX in the 1980’s did 
indeed bring about great changes in the treatment of RA, as it succeeded gold compounds, 
sulphasalazine and hydroxycholoroquine to become the number one drug of choice. More 
than a decade later the introduction of TNF-α inhibitors further enhanced the treatment of 
RA [25-27]. The current EULAR recommendations for the treatment of early arthritis 
advocate referral to a specialist within 6 weeks of the first symptoms, and the use of MTX 
as an anchor drug early in the disease course [28]. Studies such as FIN-RACO, TICORA, 
COBRA, BEST and CAMERA, speak for an early intensive treatment of RA in order to 
achieve the greatest efficacy, preserve patient functioning, and minimize joint damage [29-
33]. Reversing the pyramid from the earlier doctrine of “start low, go slow” , will often 
entail combination therapy early in the disease course and regular monitoring of disease 
activity in order to achieve the target of remission. 
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2.2 Cardiovascular disease 
2.2.1 Definitions 
2.2.1.1 Cardiovascular disease is defined by the World Health Organization (WHO) as 
“a disorder of the heart and blood vessel, and includes coronary heart disease (heart attacks), 
cerebrovascular disease (stroke), raised blood pressure (hypertension), peripheral artery 
disease, rheumatic heart disease, congenital heart disease and deep vein thrombosis” [34]. In 
this thesis I have chosen to consider acquired coronary heart disease and hypertension as the 
main clinical endpoints of the CVD process. 
2.2.1.2 Arteriosclerosis  is derived from the Greek words for artery (arterio) and stiffening 
(sclerosis) and literally means stiffening of the arteries [35]. Arteriosclerosis is the major 
cause of CVD and is sub-classified as three separate lesions, although some of these terms 
are commonly used as synonyms. Atherosclerosis is the most common form of 
arteriosclerosis, and is characterized by atheromas occurring in large and elastic arteries. 
Arteriolosclerosis, often seen in hypertension and diabetes, is the stiffening of the arterioles 
(small arteries with 1-2 layers of smooth muscle). Mönckeberg medial calcific sclerosis is, 
as the name implies, medial calcification of medium to large arteries. The condition is rarely 
seen in young individuals [36,37].  
2.2.2 Pathology of the vessel wall. 
2.2.2.1 Historical view 
Rudolph Virchow (1821-1902), often described as the “father of modern pathology” is now 
credited as being the first to describe atherosclerosis as an essentially inflammatory disease, 
more than a century before this became the prevailing conception.  However, he also 
recognized that lipids were important constituents of atheromatous lesions, describing a 
non-inflammatory “fatty metamorphosis” of the arteries as being distinguishable from other 
areas where “irritation” preceded the “fatty metamorphosis” [38]. 
The focus would later on sway towards the multifactorial causality of CVD and 
atherosclerosis. Experiments demonstrating the induction of atherosclerosis in rabbits (and 
later humans) fed on a cholesterol rich diet were pivotal in identifying cholesterol as the 
chief offender [39]. A much sited epidemiological study confirmed the clinical implications 
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of this theory in Japanese men, who by changing diets after migrating to California suffered 
from increased CVD mortality (and cholesterol levels) [40].  Atherosclerosis was thus for a 
long period viewed as a degenerative disease, characterised by lipid deposition and fibrosis, 
its inflammatory component being neglected [38,41,42]. The reduction of lipid levels in the 
population bore fruit, as mortality rates dropped and the incidence of CVD declined [43,44].  
 
2.2.2.2 Atherosclerosis 
Ross published his seminal “Atherosclerosis- an inflammatory disease” in 1999, a paper that 
became central in the modern understanding of atherosclerosis. He pointed to the important 
role of macrophages and T-lymphocytes in all types of atherosclerotic lesions from the fatty 
streak that is common in children, to the plaque verging on a rupture [41]. According to 
modern understanding, the atherosclerotic process starts with a dysfunctional endothelium 
which has somehow lost its ability to repel leucocytes and which has become permeable to 
lipoproteins [41,42,45-48]. Leucocytes are attracted by chemoattractants [42], but the actual 
attachment of the leucocytes to the intima is brought about by the expression of the vascular 
adhesion molecule-1 (VCAM-1) [42], and other adhesion molecules that are up regulated by 
pro-inflammatory cytokines in areas of non-laminar flow, typically at sites of arterial 
branching. The endothelial dysfunction is proposed to be multi-factorial in origin, with 
oxidized LDL, cigarette smoking, hypertension and diabetes acting through free radicals, as 
probable causal candidates [41,42,46,49]. The earliest atherosclerotic lesion is thus 
considered to be the fatty streak, and some of these may develop into plaques [36,47]. The 
lesions contain monocytes which ingest the lipoprotein as they develop into lipid laden 
macrophages (foam cells) and perpetuate the inflammatory state by initializing an 
inflammatory cascade attracting smooth muscle cells, platelets and more monocytes. 
Gradually a fibrous cap forms, demarcating the lesion from the lumen, and preventing 
exposure of the necrotic core developing below to the pro-thrombotic agents in the blood 
stream. The lesion has now become a plaque containing an extra cellular matrix within 
which calcification and neo-vascularization occurs [41,47]. The plaque develops in bursts, 
and plaque disruption can occur due to thinning of the fibrous cap or internal haemorrhage. 
Matrix metalloproteinases are thought to be key players in plaque disruption, and their 
release can be stimulated by inflammatory mediators and oxidized lipoproteins [42] 
As the inflammatory nature of atherosclerosis again is acknowledged, some 
pathologists have re-opened the 19th century debate concerning the role of infectious agents 
in the development of atherosclerosis. The most frequently mentioned suspects are 
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Cytomegalo virus, Chlamydia pneumoniae (C. pneumoniae) and Helicobactor pylori, but 
also bacteriae from the oral mucosa have been implicated [50]. Microbial antigens have 
indeed been identified within atherosclerotic plaques [38], and the agents are proposed to 
act either through generalized inflammation,  by direct endothelial injury due to cross-
reactivity of antibodies towards heat shock proteins produced by both microbes and 
endothelium, or  through plaque destabilization [38,45]. The proponents of the “infection 
theory” will explain the reduction in CVD mortality that has occurred in recent decades as 
partly being due to the widespread use of antibiotics [38].  However a placebo controlled 
trial that randomized 4012 patients with stable coronary artery disease to receive placebo or 
a weekly dose of 600mg Azithromax for a year, was negative with respect to the primary 
outcome of cardiovascular events and there is as of now no indication for treating CVD with 
antibiotics [51]. 
2.2.2.3 Arteriolosclerosis and Mönckeberg medial calcific sclerosis 
Arteriolosclerosis is a disease process that according to current classifications affects the 
arterioles and small arteries [36,37]. It can be divided into a hyperplastic and a hyaline form, 
both of which may give narrowing of the lumen. The hyaline form may be seen in 
normotensive patients but is reported to be most advanced in patients with hypertension and 
diabetes [37]. It is a chief morphological finding in benign nephrosclerosis and is due to 
build up of plasma components and extra-cellular matrix products. The hyperplastic form is 
often seen in patients with malignant hypertension and the thickening of the wall is thought 
to consist of smooth muscle cells and basement membrane. Mönckeberg medial calcific 
sclerosis is a calcification that affects the media of medium and large size arteries and is 
associated with kidney disease [36].  
Recently the classification of arteriolosclerosis and medial calcific sclerosis has been 
criticized for not reflecting the true pathology of the stiffening artery and for being a 
inconsequential mix of anatomical and histopathologcial conditions that are improperly 
defined [37]. The authors have suggested a novel classification scheme of:  
1. Primary arterial calcification 
2.  Fibromuscular intimal thickening.   
Under this scheme intimal calcification and the medial calcification would be termed as 
primary arterial calcification, whereas the hyperplastic form of arteriolosclerosis would be 
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termed fibromuscular intimal thickening to allow for the fact that this may also occur in the 
arteries [37]. 
2.2.3 Disease course 
The atherosclerotic disease process begins in childhood and progresses throughout life at a 
rate that is determined by individual gene-environment interactions [47]. The atherosclerotic 
plaques develop primarily in elastic and large/medium sized arteries [36]. The fatty streak, 
while considered to be the first lesion, is regularly found in regions where it is unlikely that 
a plaque will develop. The fibrofatty plaques can develop into vulnerable plaques prone to 
rupture, but it is only when the plaque encroaches on the blood supply to an organ that the 
clinical disease becomes apparent [41]. Plaque progression or rupture in the coronary 
arteries may lead to arterial occlusion and stenosis resulting in angina or myocardial 
infarction, and plaque embolization from the carotid artery may lead to cerebral infarction. 
Other possible consequences of atherosclerotic disease are peripheral artery disease with 
resultant gangrene, mesenteric occlusion, sudden cardiac death or chronic ischemic 
encephalopathy. An atherosclerotic plaque in the elastic aorta may alternatively result in an 
aneurysm through mural thrombosis and wall weakening [36]. 
A clinical manifestation of CVD indicates an increased risk of future major clinical 
outcomes. The pan-European Euro Heart survey monitored 3031 patients with stable angina 
for a median of 13 months and recorded the occurrence of myocardial infarction or death. 
They found that the hazard ratio for the combined outcome doubled if the patient had a 
history of previous myocardial infarction and with increasing angina symptom severity [52]. 
Yusuf et al. estimated that a history of hypertension gave an OR of 1.91 (CI) (1.71-2.10) for 
future myocardial infarction. The population attributable risk, which depends on the 
prevalence of a risk factor, and the risk associated with it, was 17.9% for hypertension in the 
future occurrence of myocardial infarction [53].  
Hypertension is a consequence of a disturbance in the relationship between cardiac 
output and total peripheral resistance [36]. The cardiac output depends upon the blood 
volume and is regulated via sodium homeostasis. Peripheral resistance is under continuous 
control to ensure adequate, but not excessive tissue perfusion. Vasodilators (e.g. 
prostaglandins and (nitric oxide) NO) and vasoconstrictors (e.g. angiotensin II) exert 
opposing forces on the vessel wall in order to meet this requirement. The blood pressure of 
an individual is largely explained by age, gender, BMI and dietary sodium intake, but 
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genetically determined variations in renin-angiotension system may explain some of the 
dispersion [36,54].  Blood pressure is equated by cardiac output multiplied by peripheral 
vascular resistance, the latter being determined by an array of local, humoral and neuro-
endocrine factors that work to alter vascular tone. The main vascular blood pressure 
regulation occurs at the arteriolar level, but also heart rate and cardiac contraction are 
important determinants of blood pressure. The kidney is the site of sodium regulation acting 
through aldosterone secretion (increased reabsorption of sodium from urine), production of 
prostaglandin and NO, or natriuretic factors which can inhibit sodium reabsorption in the 
distal tubule [36].  The majority of patients suffering from hypertension have no single 
identifiable cause. On the contrary; a multifactorial origin is often suspected and the patient 
is diagnosed with essential hypertension [36].  
2.2.4 Epidemiology 
CVD is the global number one cause of mortality, and 29% of global deaths are attributed to 
one or other form of CVD [34]. According to the European Society of Cardiology (ESC) 
more than 4 million people died in Europe as a direct consequence of CVD in the year 2000 
[1]. CVD mortality has fallen steadily from the 1960s in Western Europe and North 
America, and a reduction of CVD risk has occurred in groups with favourable socio-
economic resources in the developing world. The people of Central Europe or Eastern 
Europe, and individuals in poor socio-economic circumstances have unfortunately not 
displayed the same reduction in mortality as of yet [34].  
CVD is the main cause of death also in Norway, although a decline in mortality rate 
started here in the mid 1970s [44]. Of the CVDs, it is coronary heart disease and 
cerebrovascular disease that account for the majority of these deaths [44]. Norway was 
considered a high-risk country with regard to CVD mortality in 1970’s. However, the drop 
in CVD mortality mentioned above, reclassified Norway as being a country of low CVD 
mortality, with levels comparable to Greece and Spain [44]. Within Norway the inhabitants 
of the northern regions and the city of Oslo have the shortest life expectancy, and within the 
city of Oslo there is a pronounced “east:west” gradient that entails increased CVD mortality 
and greater prevalence of CVD risk factors in areas of social deprivation [55]. Smoking, 
physical inactivity in leisure time and prevalence of hypertension were the cardiovascular 
risk factors that showed the greatest geographical disparity in Oslo, in a study from 2001 
[55]. In general, the risk of all CVDs increases with age [34] and until late middle age (the 
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70s), the risk of IHD is 3-4 times higher in males than in females [44]. Women develop 
CVDs a decade later than men, and dominate the statistics on CVD hospital admissions in 
the highest age groups [44]. 
The triad of smoking, high cholesterol and hypertension are considered the most 
important risk factors for CVD in a population perspective [34,44,53]. Each factor acts as an 
effect modifier with other risk factors present, increasing the total CVD risk by many times. 
Cholesterol is the strongest predictor for coronary artery disease (CAD), whereas 
hypertension is the strongest risk factor for cerebrovascular disease [44]. The specific risk 
factors are further discussed under biomarkers.  
2.2.5 Prevention and Treatment of CVD 
According to the WHO 80% of coronary heart disease and cerebrovascular disease are due 
to behavioural factors of which an unhealthy diet, physical inactivity and smoking are the 
most important [34]. The primary prevention of CVD is the subject of a plethora of 
international and national guidelines, but the advice is very much overlapping. The ESC has 
defined the characteristics of persons who are at low risk of CVD (Figure 1) [1].  
The use of risk calculators is advocated in order to estimate the individual’s future 
risk of CVD or general mortality. The most commonly used risk calculators in primary 
prevention are the SCORE calculator of the ESC and the Framingham risk calculator. The 
SCORE calculates the 10-year risk of first fatal atherosclerotic event [1] whereas the 
Framingham predicts 10 year risk of coronary heart disease (CHD) (angina, myocardial 
infarction, coronary insufficiency and death from coronary heart disease) [56,57]. Age, sex, 
systolic blood pressure, total cholesterol and smoking habits are predictors in both 
calculators, but the Framingham also incorporates details of diabetes and treatment for 
hypertension [57]. SCORE is not valid for individuals with diabetes and it exists in separate 
versions for high and low risk countries and for those who prefer using the atherogenic 
index (total cholesterol/ HDL cholesterol) instead of just total cholesterol [1]. 
Pharmacological intervention is generally recommended to all individuals with established 
CVD, in patients with diabetes or target end-organ damage or in asymptomatic individuals 
when the SCORE 10-year risk of fatal atherosclerotic event is ≥ 5 % or the Framingham-10 
year risk of CHD is ≥20%. One of the limitations of both SCORE and the Framingham is 
that young persons do not reach the predicted risk level that necessitates treatment and that 
older individuals without elevated CVD risk factors have a predicted risk that dictates 
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treatment.  Recently the Norwegian NORRISK has been published with stratification of the 
risk level that indicates intervention according to the age of the individual [44]. The 
guidelines recommend that a person aged between 40 and 49 with a 1 % chance of death 
from CVD within the next 10 years should receive the same attention as a 50-59 year old 
with a 5% chance or a 60-69 year old with a 10% chance of CVD death. If lifestyle 
interventions do not succeed in adequate risk reduction, then the practioner should consider 
antihypertensive treatment (if blood pressure >140/90), statins for cholesterol reduction (if 
total cholesterol >5 or LDL cholesterol >3) and acetylsalicylic acid in cases of greatly 
increased risk [44]. Putting CVD prevention into perspective, the sobering fact is that the 
majority of individuals who experience a cardiovascular event would have been classified as 
being at low or intermediate risk according to CVD risk calculations [43]. 
2.3 Biomarkers  
2.3.1. Definition 
Biomarkers are quantifiable biological parameters which serve as indices of healthy or 
pathological processes, and may reflect response to a pharmacological intervention [58].  
New biomarkers are developed as we gain greater understanding of the pathological process 
leading to a disease, and these can give an indication of the patient’s position on the 
pathway to clinical disease. The use of biomarkers can allow for data collection in large 
cohorts within a relatively short period of time, and should ideally also be cheap to use and 
validated across different ethnic groups and in a variety of conditions.  
2.3.2 Biomarkers in RA 
In the field of rheumatology biomarkers have the potential to help predict which individual 
is at risk of developing RA, and when arthritis is present, who will suffer from persistent 
erosive disease, loss of function or, as the worst scenario, death. RA is a however a multi-
factorial disease and the truth will never be wholly captured by a prediction model.  
As noted above, patients with RA may have anti-CCP antibodies several years prior 
to a diagnosis and the presence of SE is associated with an increased risk of anti-CCP 
positive RA, but the incidence rate of RA is relatively low, and both SE and anti-CCP 
antibodies may also be present in healthy populations. A recent study concluded that 10% of 
the general population in Britain carried a susceptibility gene for RA [59]. Consequently, 
screening the general public for RA susceptibility is not a viable method of identifying 
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individuals at risk at the moment [21]. The European League Against Rheumatism 
(EULAR) recommendations for the management of early arthritis identified the presence of 
IgM or IgA RF, anti-CCP, high erythrocyte sedimentation rate (ESR) or C-reactive protein 
(CRP) levels, joint swellings and early erosions visible on radiographs as predictors of 
persistent, erosive disease [28].  
Measures of patient functioning have high face validity, as it is easy to appreciate the 
direct relevance of the questions to patient quality of life. Measures that reflect how a 
patient feels, functions or survives are thus considered clinical endpoints, and biomarkers 
may be used as surrogates for these endpoints after extensive validation [58,60,61].  
In the following I will very briefly highlight some biomarkers that reflect RA disease 
activity in the analyses composing this thesis. I will try to focus on how these biomarkers 
relate to what really matters, i.e.; how the patient feels, functions and survives.    
2.3.2.1 Soluble markers of disease activity 
Markers of inflammation are cross-sectionally more strongly correlated with other disease 
centred variables such as radiographically assessed joint erosions, anti-CCP and SE, than 
with the patient reported outcomes, such as fatigue, function and pain [2]. A previous 
longitudinal analyses on data from the EURIDISS cohort concluded that ESR levels 
correlated with later physical function, as reported by the Health assessment Questionnaire 
(HAQ) [62].  
CRP and ESR have been shown to be relatively stable during the disease course in 
the pre-biologic era, and to predict mortality in patients with RA [63-67].  The 
responsiveness of markers of inflammation in patients with RA treated with TNF-α 
inhibition, i.e.; the sensitivity to change, is considered to be low and is surpassed by 
composite disease activity scores and MRI imaging [68].  
Early  levels of  inflammation predict later joint erosion in patients not treated with 
TNF-α inhibition [69], and a study from the EURIDISS cohort concluded that an algorithm 
of female gender, IgM RF, anti-CCP and ESR predict radiographic progression, while the 
level of anti-CCP was the strongest independent predictor of radiographic progression [70]. 
In several cohorts the levels of RF and high levels of anti-CCP have also been found to 
predict risk of mortality in patients with RA [65,71,72]. 
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2.3.2.2 Clinical markers of disease activity 
RA disease activity can be captured by an array of clinical disease measures. The swollen 
joint counts (SJC) and tender joint counts (TJC) are intuitively meaningful. These counts are 
incorporated into composite indexes which attempt to measure additional aspects of disease 
activity. The Ritchie score is calculated by summation of the number of tender joints 
according to the Ritchie protocol [73]. The Disease Activity Score (DAS 28) is calculated 
by the following equation: 0.56 √TJC + 0.28 √SJC07 + 0.70 lnESR + 0.014 (patient global 
VAS) [74]. TJC and SJC here refer to examination of 28 joints, and visual analogue scale 
(VAS) to asking the patient to rate their present disease state on a 100 mm VAS. The 
DAS28 can alternatively be estimated by replacing the ESR with CRP values.  The Clinical 
Disease Activity Index (CDAI) is calculated as the sum of the number of swollen joints + 
number of tender joints + patient global VAS (in cm) + investigator global VAS (in cm) and 
can be calculated without performing a blood test or using a calculator. If CRP is available 
then the Simplified Disease Activity Index (SDAI) can be calculated in a similar 
uncomplicated manner [75].  
 Clinical markers of RA disease activity show moderate cross-sectional correlations 
with health status measured by the Health Assessment Questionnaire (HAQ) in several 
studies, but appear less closely related to other patient centred measures such as fatigue 
[74,76-80]. In longitudinal studies clinical markers of RA disease have been shown to be 
early predictors of later levels of joint destruction, functional decline and mortality 
[69,71,81]. 
2.3.2.3 Markers of joint destruction 
Radiographic assessment of joint damage is recommended in the management of patients 
with early arthritis [28]. The most commonly used method of quantifying damage of the 
joints in RA is the van der Heijde modification of the Sharp score (vdHSS) [82].This score 
is calculated based on the semi-quantitative assessment of joint erosions, joint space 
narrowing and joint sub-luxation.  
Joint damage will occur early in the disease course in many patients and is, if 
present, a strong predictor of the later degree of joint damage [69,80]. Measures of joint 
damage are also predictors of functional decline and increased mortality, although the 
strength of association is not very strong, and few studies find that they are independent 
contributors in prediction models of mortality [2,62,81].  
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2.3.3 Biomarkers in the prediction of cardiovascular disease. 
In the following I will present some of the central biomarkers that reflect the pathological 
stages preceding clinical CVD. I have chosen to give most attention to the biomarkers that 
are used as surrogate endpoints or predictors in the individual papers of this thesis. 
2.3.3.1 Serological markers of arterial vulnerability 
CRP  
CRP belongs to the pentraxin family of proteins and it’s production is mainly mediated by 
IL-6 [48]. The level of CRP in an individual is partly determined by genetic factors and 
partly by traditional CVD risk factors such as smoking, diabetes type II and adiposity 
[46,48,83,84]. In pathological situations such as inflammation, infections or tissue trauma, 
the CRP level can increase substantially. Increased levels of CRP in the high sensitivity 
range are associated with a higher risk of CV morbidity and mortality in the general 
population [85,86]. In recent years several assays which quantify CRP below 3mg/L, in the 
high sensitivity range, have thus been developed. The lower limit of reliable quantification 
can be as low as 0.15mg/L in some assays [87]. 
Whether CRP is a causal factor in atherosclerosis or just a convenient biomarker 
downstream of the real culprit(s) is still not definitively established [88]. CRP is claimed to 
have atherothrombotic effects on endothelial cell, platelets, macrophages and on smooth 
muscle [48,89]. Additionally, CRP has been shown to up regulate the angiotensin type-I 
receptor that facilitates angiotension II mediated vascular smooth muscle migration and 
proliferation [90]. Endothelial cells incubated with purified CRP exhibit a downregulation 
of NO production, and increased IL-18 levels, encouraging the adhesion of monocytes to the 
endothelium [89]. Intriguingly, a later study reported the opposite finding of increased NO 
bioavailability after incubation of blood vessels in purified CRP [91].  The finding was 
further confirmed in a sub-study showing that endothelial dysfunction follows 
inflammation, in this case after a Salmonellae typi vaccination in humans, but that it occurs 
prior to the rise of CRP [91].  
 In conclusion, the sway of opinion seems to be towards the view that CRP is 
probably not a causal factor for the development of coronary artery disease [45]. This view 
has gained support from recent population studies showing that polymorphisms in the gene 
determining CRP levels were not predictors of CVD disease [83].  
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NT-proBNP 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the biologically inactive N-
terminal fragment of the active hormone B-type natriuretic peptide (BNP) and is part of a 
family of natriuretic peptides that cause vasodilation, natriuresis and smooth muscle 
modulation in response to myocardial stretch [92-94].  Granules were identified in the 
atrium of the heart in the 1950s, but it was De Bold working on murine hearts in the 1970s, 
who discovered that atrial extracts caused  natriuresis when injected intravenously [92,95]. 
BNP is produced in both atriums and ventricles in response to myocardial stretch 
[92,94,96,97]. NT-proBNP and BNP release may however, also be up regulated by 
proinflammatory cytokines [98]. NT-proBNP is partly metabolized in the renal proximal 
tubule, and reduced renal function may partially accounts for the age-related increase in NT-
proBNP levels in the general population [93,94]. The principal pathway for clearance of 
BNP and possibly NT-proBNP is however, through endocytosis and degradation in cells 
along the vascular pathway [92].  
The level of NT-proBNP predicts all-cause and cardiac mortality, and morbidity in 
the general population as well as in cohorts of patients with heart failure, kidney disease and 
stable coronary heart disease [96,99-102]. Significant heart failure is considered unlikely in 
an untreated patient with a low-normal NT-proBNP, [103] but due to a limited specificity, 
diagnoses such as sepsis and kidney failure must also be considered with high levels [104]. 
A multi-marker approach to the diagnosis of cardiovascular events or death has been 
investigated, and NT-proBNP was found to be the strongest independent predictor, with 
regard to mortality, in populations with and without previous CVD [105].  
 
Lipids 
Low-density lipoprotein (LDL)-cholesterol is considered to be a major cause of CVD and 
has thus been identified as the main target for cholesterol-lowering therapy [106]. The 
central position of lipids in CVD risk estimation is illustrated by the INTERHEART study 
which found that the variable with the highest population attributable risk was a high ratio 
of apolipoprotein B: apolipoprotein A, explaining close to 50% of the risk for incident 
myocardial infarctions (MI) [53]. 
A longitudinal study analyzing data from 300 000 patient found that assesment of 
two lipoproteins (either total cholesterol and HDL, or apolipoproteins) was sufficient to 
predict CVD risk. A 1 standard deviation (SD) increase in non-HDL (Total cholesterol – 
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HDL cholesterol) translated to a 50% increased hazard ratio (HR) for CHD (the same HR as 
LDL cholesterol and apolipoprotein B), and a 12% increased risk of ischemic stroke. 
Triglycerides on the other hands were not independent predictors in models that included 
non-HDL and HDL levels [107].  
According to Bradford Hill, the strongest evidence of causations stems from studies 
showing that an intervention on a perceived risk factor results in a reduced frequency of the 
unfavourable event [108]. The causal relationship between lipids and CVD is in this context 
very well proven. The 4S study showed that long term treatment with simvastatin prevented 
CHD, and in the following year pravastatin was shown to prevent MI and death from CVD 
[109,110]. The current doctrine is one of intense lipid lowering, especially for individuals 
with a proven history of CVD [1,111]. 
2.3.3.2 Functional makers of arterial vulnerability 
Endothelial function 
In the coronary arteries the level of functioning NO can be measured through an invasive 
test.  Acetylcholine has a vasoconstricting effect on vascular smooth muscle and an 
opposing vasodilatory function via endothelium mediated NO release (working through 
signal transduction on G proteins) [112]. A resultant vasoconstriction upon injection of 
acetylcholine into the left ascending coronary artery is thus taken as a sign of abnormal 
endothelium dependent flow reserve. This test has been shown to predict CHD (MI, heart 
failure and PCI) [113,114]. 
Celermajer and Deanfield developed the procedure towards a non-invasive and 
reliable estimation of endothelial function. Flow Mediated Dilatation (FMD) depends upon 
the increased shear stress flow that is the result of reactive hyperemia achieved by inflating 
a cuff placed around the proximal forearm to supra-systolic pressure. There is a subsequent 
local release of NO and dilatation of the brachial artery which can be assessed by an 
ultrasound device [112]. As a control, the response of the brachial artery to a non-
endothelium dependent vasodilator such as sublingual glycerol trinitrate (GTN) is recorded 
[115,116]. Brachial FMD correlates with the severity of coronary artery disease, and is an 
independent predictor of coronary artery disease [117], and cardiovascular events in a model 
that include the Framingham risk score [118]. 
Other, less validated, methods of assessing endothelial function exist. The change in 
augmentation index (AIx) that occurs as a consequence of consecutive administrations of 
salbutamol and nitroglycerin can give an estimate of the endothelium dependent and 
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independent endothelial function, respectively [116]. Soluble biomarkers such as adhesion 
molecules can be measured in the circulation, and are associated with the presence of 
atherosclerosis [119]. These molecules sit at the cross-roads between inflammation and 
endothelial dysfunction, and the multi-factorial origin makes interpretation of results 
difficult [112]. Additionally, the principle of reactive hyperemia inducing shear stress is 
utilised in a number of novel devices, including the Itamar, which gauges change digital 
blood flow in response to forearm ischemia and quantifies the reactive hyperemia index 
(RHI) [120]. The role of NO release in digital reactive hyperemia has been proven, and the 
RHI has been shown not only to correlate with both FMD and coronary endothelial 
function, but to predict future cardiovascular events [120-123].   
 
Brachial blood pressure 
A measurement of systolic and diastolic pressure is arguably the cheapest and most 
frequently used biomarker to assess CVD risk, and both systolic and diastolic pressures 
have been targeted in risk reduction [115].  A meta-analysis of 61 prospective observational 
studies examined hypertension as a predictor in 56 335 cardiovascular deaths [124]. The 
study found that in patients aged between 40 and 69 and without previous CVD, an increase 
of 20 mmHg in systolic pressure above 115 mmHg, or an increase of 10 mmHg diastolic 
pressure above 75 mmHg, doubled the risk of death from IHD and stroke. As a consequence 
of this, and similar findings from the Framingham cohort, the 2007 ESC guidelines for the 
management of arterial hypertension categorises a systolic pressure < 120 mmHg and 
diastolic pressure < 80 mmHg as optimal. Systolic pressures in the range of 120-129 and/or 
diastolic pressure 80-84 are described as normal, systolic pressure 130-139 and/or diastolic 
85-90 as high normal and systolic pressure >140 and/or diastolic > 90 mmHg as 
hypertension [125]. 
The ESC guidelines recommend measuring blood pressure using a mercury 
sphygmomanometer, or a validated non-invasive ausculatory or oscilliometric semi-
automatic device. The patient should be allowed to rest before the measurements, and the 
measurements should be repeated several times and on several occasions. One should ensure 
that the cuff correctly fits the overarm of the patient. A 24-hour blood pressure measurement 
may provide useful information both when diagnosing hypertension and when assessing the 
effect of medication [125].   
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Low diastolic pressure combined with elevated systolic pressure (isolated systolic 
hypertension) equates with a high pulse pressure (PP) (systolic-diastolic pressure) 
[125,126]. PP is a measure of stiffness in the arteries but has been found to be a weak 
predictor of future mortality when derived from the pressure measurements in the brachial 
artery [124].  
 
Arterial stiffness  
Central arterial stiffness can be assessed non-invasively by pulse wave analysis [127,128]. 
The available apparatus utilizes applanation tonometry to record pressure readings in real 
time. The probe obtains accurate pressure waveforms as it equalises the circumferential 
pressure by slightly flattening the artery against a bony base. Two theoretical principles are 
central in the understanding of pulse wave analyses. Pressure measured in an artery is not 
only a product of the cardiac output divided by systemic resistance, but also of a reflected 
pressure wave that arises from bifurcations and other hindrances that the efferent pressure 
wave encounters. Secondly, that increasing arterial stiffness corresponds to increasing pulse 
wave velocity (PWV). There is increasing recognition that progression in arterial stiffness 
will impact on the heart by enhancing wave reflection and thus increasing pressure in the 
ascending aorta and ventricles [129,130].  
Central pressure measurements are estimations of the systolic pressure in the 
ascending aorta. The peripheral muscular arteries exhibit greater arterial stiffness than the 
central elastic in young and healthy individuals. This gradient of increasing stiffness 
translates to a PP amplification of peripheral PP > central PP. The amplification is 
diminished as central stiffness increases, with age or greater prevalence of risk factor for 
CVD [131].  A transfer function is applied to the pressure measurements of the wave in the 
radial artery in order to estimate central systolic pressure and the AIx.  The transfer function 
that is commonly used today has been validated against invasively measured central 
pressures [132]. Indeed, central systolic pressure derived from sphygmomanometry has 
been found to correlate with invasively measured aortic pressures [132] and with left 
ventricular mass index [133]. The transfer function has however been criticised for relying 
on brachial pressure measurements and alternatives such as calibrating the transfer function 
to central pressure measurements derived from carotid artery tonometry have been 
suggested [130,134].  
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The AIx is an estimation of the augmentation of central pressure that is caused by 
wave reflection and is defined as the change in pressure between the second and first 
systolic peaks as a percentage of the pulse pressure [132] (Figure 2). The AIx has been 
shown to predict cardiovascular events and death in populations of hypertensive and 
atherosclerotic patients [135-137] 
Aortic PWV is a measure of the velocity in the aorta and is currently accepted as the 
gold standard measure of arterial stiffness. PWV can be derived from knowledge of both the 
transit-time for the pulse wave travelling from the heart to two sites, and the distance 
between these sites [127,134]. The carotid-fermoral PWV (cfPWV) estimates aortic PWV 
between the site on the carotid and on the femoral artery, where the pulse is most strongly 
palpated. The recordings of the foot of the pressure wave at the carotid and femoral artery 
are gated to an electrocardiogram (ECG) as a measure of transit time. There are several 
methods of estimating the distance travelled, but frequently the distance between the supra-
sternal notch and the measurement site on the carotid artery is subtracted from the distance 
between the supra-sternal notch and the site on the femoral artery [134].  The cfPWV is an 
established independent predictor of all-cause and cardiovascular mortality in both 
populations with and without pathological conditions [136,138-144].  
 
Ankle-brachial index 
The Ankle-brachial index (ABI) has been used for many years to assess the severity of 
peripheral arterial disease, but is also an indicator of generalized atherosclerosis. The 
convenient methodology is an obvious advantage. The standardized method entails a 
systolic pressure measurement by a pulse sensor or doppler probe in the posterior tibial 
and/or dorsalis pedis arteries, and the lowest of the distal pressures then being divided by 
the brachial systolic pressure [145]. This marker is inversely related to cardiovascular risk 
factors such as smoking and diabetes and low levels are related to an increases incidence of 
mortality, MI and stroke [145,146]. 
2.3.3.3 Structural markers of arterial vulnerability 
IMT/plaque 
Ultrasonography of the carotid artery can identify preclinical atherosclerosis either as an 
atherosclerotic plaque or as an increased intima-media thickness (IMT). Carotid IMT 
evaluation by ultrasonography is considered a valid and reliable method and is usually 
measured in one, or more, of these six locations; the near and far wall of the internal and 
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common carotid artery or the bulb region [147,148].The segment chosen for measurement 
varies between studies, and this is a possible source of variability [149]. IMT is a significant 
predictor of MI and stroke, although the correlation to coronary atherosclerosis is not very 
strong [147,149,150].  
The presence of plaques in the carotid artery is a strong sign of an increased risk for 
cardiovascular events [151,152]. However, no agreement exists regarding the definition of 
when an intimal thickening becomes a plaque, and the decision will often depend on several 
criteria. Salonen’s classification was based on the most advanced lesion and described 
intimal-medial thickening if the distance between the intimal and luminal surfaces was 
>1mm. In this paper, a plaque was defined as a distinct area with mineralization or focal 
protrusion, and became classified as stenotic if it obstructed more than 20% of the lumen 
[151]. Other papers have defined plaque as an irregular thickening ≥1.5mm [153] which, in 
the recent ARIC study, must be combined either with an irregular shape or abnormal wall 
structure in order to qualify as a plaque [152].  
 
Coronary artery calcium  
Computer tomography (CT) detects calcification of the coronary arteries, an early and 
highly specific sign of atherosclerosis [154,155]. The Agatston score is calculated for each 
patient by summing the number of lesion in the four coronary arteries after each has been 
multiplied by a density factor for the area [154].There is however evidence that the coronary 
coverage score is a better predictor; this is the percentage of arteries with lesions [154,155]. 
Most information on (coronary artery calcium) CAC score comes from studies using 
electron beam CT (EBCT), but also a multi-detector CT will generate highly reproducible 
data. The multi-detector CT does, however, give a larger radiation dose than the EBCT, 
which in itself can reach a radiation dose equivalent to 20 chest radiographs, approaching 
the limit where there might be a small but measurable increased risk of cancer [156]. The 
CAC has been found to predict CV events and to improve the discrimination of models 
which included of Framingham risk score [157]. 
2.3.3.4 Multiple biomarkers 
Risk scores derived from multiple biomarkers are viable instruments that aid the clinician 
who wishes to assess the CVD risk of an individual [1]. The Framingham risk calculator 
was developed from data collected at the 12-year follow-up of the Framingham examination 
of white middle class Americans [158]. The risk score has been elaborated on and updated 
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many times but the endpoint of CHD events (defined as angina, MI, coronary insufficiency 
or CHD death) has remained constant[56,57]. The validity of the risk model has been 
examined in several studies and has been found to vary between populations [159]. For this 
reason the European SCORE project was initiated, culminating in a risk model that predicts 
death from CVD based on data submitted from 12 European countries and including over 
205 000 individuals, contributing close to 8000 deaths[160]. 
2.4 Cardiovascular disease in RA  
2.4.1 The epidemiology of CVD in RA 
Mortality in general and CVD mortality specifically are both increased in patients with RA 
[2]. About 40% of the deaths in the cohorts included in the meta-analyses performed by 
Sokka, were due to CVD, and this was the most frequently attributed cause of death [2]. 
Kvalvik et al. has reported similar findings in a Norwegian cohort of patients with RA; a 
SMR of 1.49 and CVD as the dominant cause of death[161]. Aviña-Zubieta et al. identified 
24 papers that addressed a CVD outcome in RA, (including cerebrovascular accidents) and 
calculated a meta-SMR of 1.5 for cardiovascular mortality. The mortality due to 
cerebrovascular disease was almost equivalent to that of IHD (1.52 vs. 1.59) [3].  
The absolute risk of CVD death is highest for elderly males with RA, whereas the 
relative risk is highest for young females [162,163]. The increased risk is evident already 
early in the disease course.  A study from the English early RA study (ERAS) found an 
increased mortality within the first seven years of disease, although the authors mention that 
these patients were included before biological therapies became an option [65].  Patients 
with inflammatory polyarthritis, including RA, have also been shown to be at a higher risk 
of being admitted to hospital with CVD within the first seven years after symptom debut 
[164]. 
An increased risk of death within 30 days post-MI for patients with RA has been 
reported by several groups [5,165]. The frequency of unrecognized MI, and congestive heart 
failure, has by others been found to be increased in patients with RA included in the 
Rochester cohort [4,166].  Also in this cohort the increased risk is apparent early in the 
disease course, as the patients with RA were more likely to have suffered an MI in the two 
years prior to RA diagnosis than the sex and age matched control population [4]. 
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2.4.2 Biomarkers of CVD in patients with RA 
In the following I will give an overview of studies, published by the early days of this 
thesis-work, which concern important biomarkers for CVD in patients with RA. 
2.4.2.1 Serological markers of arterial vulnerability 
Markers of inflammation 
The level of inflammation, measured by ESR, has been found to predict mortality in patients 
with RA in several studies [65,66,71,167] and has also been linked to the development of 
heart failure[168]. A longitudinal study from the Norfolk Arthritis Register found that 
baseline CRP levels predicted future CVD mortality [64]. The CRP levels in patients with 
RA are also partially predicted by traditional CVD risk factors such as smoking and BMI 
[84]. Wållberg-Jonsson has reported that the adhesion molecules E-selectin and soluble 
intracellular adhesion molecule (ICAM) are  associated with the presence of plaques and 
increased IMT, respectively[169], while other studies have suggested that level of cytokines 
such as IL-6 may be more strongly linked to endothelial dysfunction than the traditional 
markers of inflammation [170]. 
 
NT-proBNP 
A pubmed search at the time of planning this thesis did not identify any papers concerning 
either BNP or NT-proBNP levels in patients with RA. 
 
Lipids 
Heterogeneous findings concerning the lipid profiles of patients with RA have been reported 
[171,172]. An adverse lipid profile has been found in cohorts across a range of disease 
durations and activity states. In addition, the lipid components have been found to be 
particularly proatherogenic due to oxidization caused by inflammation [46].  
Whether patients with RA have increased or reduced levels of total cholesterol is a 
question of contention. Early in the disease course, total and LDL cholesterol have been 
found to be elevated compared to controls [173]. This finding is strengthened by the 
observation that total cholesterol in blood-donors, who later develop RA, is increased prior 
to clinical disease debut [174]. Chronic high levels of inflammation have, on the other hand, 
been shown to correlate with reduced total cholesterol levels (HDL, LDL and VLDL), [175] 
and some studies have found that patients with RA have lower total cholesterol than 
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matched controls [176-178]. Several possible mechanisms have been explored. Lipoprotein 
lipase has been found to be decreased in adipose tissue and skeletal muscle in inflammatory 
conditions [175]. Additionally, an increase in the production of acute phase proteins by the 
liver may lead to reduced lipoprotein production [175], and increased activity by the 
reticuloendothelial system may result in increased clearance of LDL-cholesterol [179]. My 
impression, however, is that the majority of studies have found that the level of LDL 
cholesterol to be statistically similar in patients with RA and controls, but that the HDL is 
reduced in these patients, contributing to a decreased total cholesterol and resulting in an 
adverse atherogenic index [171,180-182].  
An early report on the effect of disease modifying agents on the lipid profiles of 
patients with RA was published in 1997, concluding that treatment with 
hydroxychloroquine had a beneficial effect on serum lipids [183]. Later studies showed that 
both corticosteroids and DMARDs can have a beneficial effect on the lipid profile of 
patients with RA in that the subsequent increase of HDL improves the atherogenic index 
[173,184]. Treatment with TNF-α inhibitors have also been found to alter the lipid profile in 
patients with RA by increasing HDL, and thereby also total cholesterol, although the 
changes are small and possibly temporary [185-187] 
2.4.2.2 Functional markers of arterial vulnerability 
Endothelial function 
The first study reporting reduced endothelial function in RA was designed as an 
intervention, concurrently showing that the dysfunction was ameliorated by TNF-α 
inhibition [188]. The case-control part of the study, including only 10 patients with RA, 
found significantly reduced endothelium dependent and independent vasodilation in patients 
with RA, but it was only the endothelium dependent dilatation that improved upon 
treatment. This last finding has been confirmed by others, although the cohorts studied have 
all been very small [189,190]. Endothelial dysfunction has been reported early in the RA 
disease course [188,191], and also in young RA patients without any clinical CVD risk 
factors [192,193]. Gonzalez-Juanatey et al. have suggested an association between the SE 
*04 allele and endothelial dysfunction attenuation [194].   
No studies dealing with the RHI in patients with RA were found. 
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Blood pressure 
The Nurses’ Health Study, relying on patient self-reported data found no increased reporting 
of hypertension in patients with RA [195],  a finding that was confirmed in the Rochester 
cohort and by the much smaller Alkaabi study which drew on assessments of age and sex 
matched cohorts[4,196]. However, Del Rincon et al. reported an increased prevalence of 
systolic hypertension in patients with RA after adjusting for differences in age and sex, and 
McEntgart et al found slightly increased diastolic pressures [176,197] .  
 
Arterial stiffness and central pressure 
AIx and PWV are both increased in patients with RA when compared to population controls 
[198,199]. Major publications on arterial stiffness, published by June 2010,  in RA are 
summarized in Table 1 and 2. Two papers that were published at the start of this thesis are 
highlighted in italics [198,199]. AIx and PWV were both reported to be increased in patients 
with RA in these cross-sectional studies, although the studies were both very small 
including 14[198] and 8 patients [199] respectively. In 2003 Wong  and van Doornum 
reported on reduced small and large artery elasticity in two small studies (53 and 25 patients 
with RA respectively), and found an inverse association with measures of inflammation 
[200] and Sharp score [201]. However, the validity of this computerized version of the 
Windkessel model has since been questioned [202]. Roman et al. found increased regional 
stiffness in patients with RA using the arterial stiffness index, Young’s modulus and 
Peterson’s elastic modulus, three measures that integrate pressures derived from the 
sphygmocor with estimations of distension obtained from ultrasonographic examinations of 
the carotid artery[203].   
  
Ankle-brachial index 
Patients with RA were more likely to have a low ankle-brachial index than matched controls 
RA in two studies [196,204].   
 
2.4.2.3 Structural markers of arterial vulnerability 
IMT   
IMT has been found to be increased in patients with RA in several case control studies [204-
206], although Roman et al. reported lower IMT in patients with RA compared to 
population controls [207]. The studies that have investigated the association between 
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disease activity and IMT are heterogeneous in design and findings. Increased IMT is 
associated with increased disease duration, radiographically assessed joint destruction, and 
reduced functioning, but not markers of inflammation in the study by Kumeda et al, whereas 
others have reported an association between markers of inflammation and IMT [208,209]. 
Del Rincon attributed 11-16% of the variance in IMT to demographic variables, whereas 
RA manifestations explained 1-6% [208]. 
 
Plaque 
Patients with RA have a greater prevalence of plaques in the carotid artery compared to 
population controls [207,210]. Dessein et al. and Del Rincon et al. both report that a 
combination of traditional CVD risk factors with variables of RA disease activity give the 
best models for explaining the presence of plaques  in cross-sectional studies [153,208] 
 
Coronary arterial calcification 
CAC has been found to be increased in male patients with RA and in patients with RA of 
more than 10 years duration [211,212]. CAC may be associated to the metabolic syndrome, 
RA disease duration and markers of inflammation [211-214]. 
 
3. Aim and research questions   
3.1 General aim  
The aim of this thesis was to investigate the association between RA disease activity and 
markers of CVD risk in a cross-sectional and longitudinal perspective. CVD risk profiles 
were compared between patients with RA and community controls. The utility of NT-
proBNP in the prediction of mortality in RA was also investigated.  
3.2 Main research questions 
1. Are markers of CVD risk and RA disease activity cross-sectionally associated? 
 
2. Do biomarkers of CVD risk differ between patients with RA and population 
controls? 
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3. Is there a longitudinal association between RA disease activity and markers of CVD 
risk? 
 
4. Do levels of NT-proBNP predict general mortality in patients with RA and how does 
this biomarker compare to known predictors of mortality in RA? 
 
4. Material and Methods 
4.1 Populations 
The four papers in this thesis draw on data collected in three cohorts established at 
Diakonhjemmet Hospital, Oslo, Norway. 
 
1. The EUropean Research on Incapacitating DIsease and Social Support 
(EURIDISS) cohort was established in Oslo in 1991 [215] and was, as the title states, 
initially a multicentre European project investigating social support in RA as a model of 
chronic disease. Patients with RA of short duration (≤ 4 years) were identified by searching 
medical records at the Department of Rheumatology at Diakonhjemmet Hospital, Oslo and 
at Martina Hansen’s Hospital in the neighbouring county of Akershus. The inclusion criteria 
were a diagnoses of RA according to the ACR 1987 criteria [9], disease duration ≤ 4 years, 
age 20-70 years and a residential address in Oslo or Akershus. The exclusion criterias were 
Steinbrocker class IV, meaning that the patient was confined to bed or wheelchair, and 
expected to be lost to follow-up. 326 patients were eligible for inclusion of which 268 
patients agreed to participate in the study. 30 patients were subsequently excluded, 21 did 
not fulfill the 1987 ACR classification criteria, six planned to move out of the Oslo region 
and three were immigrants with difficulties communicating in Norwegian [216]. 238 
patients were included at baseline and living patients were subsequently asked to attend the 
follow-up visits after 1, 2, 5, 10 and 15 years. 
 
2. The Oslo Rheumatoid Arthritis Register (ORAR) was established in 1994 but is 
continually updated by searching the hospital records for patients given a diagnosis of 
arthritis or a related condition. The medical record of the patient in question is then hand 
searched and patients fulfilling the 1987 ACR criteria are included in the register. The 
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ORAR has been validated for its completeness for patients aged 20-79 through a postal 
survey of 10 000 inhabitants of Oslo [11]. The patients in the ORAR have been asked to 
participate in regular follow-up data collections. From this register, 90 patients who had 
participated in the 1997 data collection, and who had reported a disease onset between 1993 
and 1997, were identified. Of these patients, eight were deceased and the survivors were 
asked to participate in the 2007 data collection. 
 
3. The community controls cohort has recently been established.  Community 
controls were selected at random by Statistics Norway, but we attempted to match controls 
to patients in our cohorts in strata by using details of age, sex and residential area. Statistics 
Norway will not provide details of education or income but the residential area in Oslo can 
to some extent be used as a surrogate of social class [217]. Oslo is divided into 17 boroughs 
and each borough is indexed for living conditions [218]. This index is based on the number 
of residents receiving state benefits including unemployment payments and mortality. For 
the stratification, details from EURIDISS and ORAR patients asked to participate in the 
2007 data collection were pooled with patients participating in an Oslo Ankylosing 
spondylitis cohort, also located at Diakonhjemmet Hospital. We chose to combine our 
cohorts for this stratification for financial reasons as it will enable us to also use data from 
the community cohorts in other comparative studies.  
Details of the study cohorts used in each paper are presented in Table 3 
4.2 Data collection 
In each study, patients who were eligible for inclusion in the project received a letter 
informing them in detail about the investigations that were to be carried out, and asking 
them to participate in the data collection. The patient information and consent form were 
approved by the local ethical committee. The data collection was organized as evening 
clinics at which the patient moved through a series of “stations”. The stations were manned 
by appropriate healthcare professionals (nurse, medical students and doctors). For the data 
collections that were performed specifically for the papers in this thesis (10-year 
EURIDISS, 15-year ORAR and community controls) we aimed to have stability with regard 
to personnel, apparatus and localization through all cohorts and over the entire period. 
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Demographics and utility 
Demographic and health status variables were collected by self-reported questionnaires, but 
the patients could consult medical students hosting the data collection if in doubt on how to 
answer.  Health status was measured by the HAQ, a questionnaire that captures how patient 
function in several areas of daily life [76], and by the generic Nottingham health profile 
(NHP) [219]. 
4.2.1 Biomarkers of RA disease activity 
Soluble biomarkers 
Details of the analytical procedure for each soluble biomarker are presented in the relevant 
papers. NT-proBNP, anti-CCP and SE were batch analysed from frozen sera/full blood that 
had been stored at -70ᵒ C from 1992 (paper 1 and paper 3) and 1997 (paper 1 and paper 4). 
Biomarkers analysed at the 2007 examination were analyzed consecutively, ESR by the 
Westergren method, CRP and total cholesterol by COBAS 6000, and NT-proBNP by a 
Modular E 170 device, both by Roche Diagnostics, Basel, Switzerland.  Anti-CCP and IgM 
RF at this data collection were batch analysed from sera that had been frozen for a 
maximum of three years using the ELISA method (Inova Diagnostics ®, San Diego, USA 
and an in house method respectively) as previously reported [70] 
 
RA disease activity 
A trained study-nurse performed clinical examinations in order to determine the number of 
swollen and tender joints. Joint destruction was measured by radiographic damage of the 
hands and scored according to vdHSS at each time point. [82] 
 
Markers of CVD risk 
Blood pressure (BP) was measured after a 5-minute rest in a supine position using the 
OMRON M7. Several measurements were made until two measurements differed by ≤ 5 in 
both systolic and diastolic mmHg and heart rate, and an average was then calculated.  
We performed pulse wave analysis assessments using the Sphygmocor apparatus 
(Atcor Australia). We measured the carotid-femoral cfPWV between the site on the carotid 
and on the femoral artery where the pulse was most strongly palpated. The recordings of the 
foot of the pressure wave at the carotid and femoral artery were gated to an ECG of cardiac 
activity as a measure of time. Several recordings were made in each patient (median 5, 
range 1-20 for AIx, and median 3, range 1-10 for PWV). For the AIx analysis our primary 
 38
objective was to obtain recordings with an acceptable wave form and an operator index >85. 
The operator index is the apparatus internal control index that is calculated on the basis of 
sufficient pulse height and minimal pulse wave variation [220]. In cases failing this 
threshold we accepted three measurements with an index >65 or, in a few very difficult 
cases (3% of the total number of recordings), measurements with an index >50 and an 
acceptable waveform. The recordings considered to have the highest quality according to 
pre-determined requirements were selected for further analyses [220]. Patients suffering 
from atrial fibrillations were excluded from the analysis. Based on prior studies, the patients 
were requested to abstain from food, drinks (except for water) and smoking for at least 3 
hours prior to examination [127].  
The RHI, also called the digital hyperaemic response was measured using the Itamar 
apparatus ® [120]. The patients were asked to recline on a bed in a comfortable position and 
probes were attached to bilateral index fingers. A sphygmo-manometer cuff was wrapped 
around an upper arm. After a 5 minute recording of the digital pulse, the cuff was inflated to 
200mmHg and the recording examined for any sign of pulsatile activity on the occluded 
side, in which case the cuff was further inflated, although not above 300mmHg. After 5 
minutes occlusion the cuff was released and a further 5 minutes of recording was made 
during which the hyperaemic phase occurred. The RHI was calculated by the software 
installed on the Itamar.  
B-mode ultrasonographic examinations were performed on bilateral common carotid 
arteries using a GE Vivid 7 ultrasound scanner (GE Vingmed Ultrasound, Horten, Norway) 
with a 12 Mhz probe (9-14) linear matrix array transducer. The images were analysed off-
line from jpg images. The intima-media thickness (IMT) of a 5mm long section of the far 
wall, 10 mm proximal to the carotid bulb, was obtained by the AMS analysis software 
(Artery Measurement System, Thomas Gustavsson, Gothenburg, Sweden). Each 5 mm 
section generated numerous calculations indicated by mean and median values. The latter 
were used when comparing study groups.  
The Framingham 10-year risk of coronary heart disease and the SCORE 10-year risk 
of CVD related death were both calculated using standardized risk calculators [1,56] 
4.3 Statistical analyses 
All statistical analyses were performed using Statistical Package for the Social Sciences 
(SPSS) 14-17 
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4.3.1 Examination of data 
Continuous variables were plotted for normality. Skewness is a measure of the symmetry of 
a variable, while the degree of kurtosis estimates how similar the distribution is to a 
Gaussian distribution [221]. A skewness and kurtosis below 1.5 was considered acceptable 
for analyses requiring normal distribution of data. In case of non-normally distributed data 
we performed a transformation to the logarithm of the 10th base (paper 1) or to the natural 
logarithm (paper 2-4). Variables that could have a score of 0 were difficult to transform, and 
were therefore dichotomized at the median (e.g. HAQ scores paper 4).  
4.3.2 Bivariate examinations 
All four papers include a table of bivariate comparisons of crude data. For these analyses 
cross-tabulation with χ² statistics were used for counts, while student t-test or Mann-
Whitney U test was used for data with normal and non-normal distributions as appropriate. 
4.3.3. Examinations of associations 
In all models the correlations between variables were investigated using Pearson’s and 
Spearman’s coefficients for normal and non-normally distributed data, respectively. Paper 1 
and paper 2 investigated the cross-sectional associations between markers of CVD risk and 
measures of RA disease activity.. For these analyses we used univariate linear regression 
with adjustments for age and sex as a first step of the regression analyses. The equation of 
the linear regression analyses is: Y= a + βX. This equation gives an estimation of Y for any 
X, by fitting a straight line in which” a” is the intercept and β is the slope [222].  
Variables that showed an association with the dependent variable at the pre-specified 
level of significance (usually p≤0.1) were included in multivariate linear regression models, 
and variables were removed according to the level of significance until all variables 
included in the model were significant at the level of p<0.05. As age and sex were perceived 
to be of fundamental importance they were included in all models regardless of the level of 
significance. The validity of the final models was verified in a number of ways. Cooks 
distance was plotted, and the stability of the model was ensured after removal of outliers. 
Previously excluded variables were consecutively entered into the model to examine for 
additional confounding.  
In paper 1 data from several time-points were used in a mixed model repeated 
analysis. This approach controls for multiple testing of the same patient in the calculation of 
the confidence intervals. Another advantage of the mixed model repeated analysis is that it 
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is able to tackle missing data at one time-point, without removing the patient from the 
model estimation [223]. 
4.3.4 Prediction models 
In papers 2, 3 and 4 we have performed analyses were the dependent variables were 
dichotomized and we therefore used logistic regression analyses for these analyses. The 
equation for the logistic regression analyses is log odds of outcome= (β0 + x1 + β2x2), 
where the β is the regression coefficient of the associated exposure (x).  β0 is the log odds of 
the group that has not been exposed to x (x=0). Through the logit function the log odds of 
an outcome through the regression analyses can be transformed into an estimation of the 
probability of that outcome [222]. The multivariate logistical regression model was 
constructed in the same manner as the multivariate linear model. The validity of the final 
model was verified by checking for confounders among previously excluded variables and 
by ensuring that the model remained stable after the removal of outliers.  
Individual risk prediction was estimated by calculating the sensitivity, the specificity 
and the accuracy of the model. These are defined by the following formulae.  
Sensitivity = cases correctly identified/ number of cases 
Specificity = non-cases correctly identified/number of non-cases  
Accuracy= number of cases correctly identified + number of non-cases correctly identified / 
number of true positive+ false positives + true negatives + false negatives [224]. 
The ability of the model to discriminate for the outcome of interest can be examined 
by a receiver operating characteristic (ROC) curve. This graph plots the sensitivity of the 
model against 1-specificity. A large area under the curve (AUC) indicates that the model 
shows good discrimination, and the AUC must be >0.5 if the model is to be considered 
better at predicting the outcome of interest than tossing a coin [224].  
4.3.5 Statistical assessments of biomarker validity 
The repeatability, i.e. the agreement between measurements repeated under identical 
conditions, of the biomarkers for CVD risk was assessed by calculating the intra-reader 
correlation coefficient. The reproducibility of the assessments was assessed by reliability 
calculations. The agreement between measurements under slightly differing conditions was 
assessed by calculating the inter-reader correlation coefficient [222,225].  In both cases the 
variance in results between patients is divided by the sum of the variance between patients 
pluss the variance in the difference between readings.  
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The number of community controls needed in order to achieve 80% power for 
detecting clinically significant difference in several measurements at the 5% level of 
significance was calculated prior to asking participants. (Power is here defined as the 
probability that a study detects a statistically significant difference of a given magnitude 
between samples [225]). 
4.4. Legal and ethical considerations 
The patients and community controls were insured through the “The Norwegian System of 
Compensation to Patients” while on the hospital premises. All studies were conducted in 
accordance with the Declaration of Helsinki on ethics in medical research [226]. The 
research protocol at baseline and on each subsequent data collection was approved by the 
Regional Committee for medical research ethics. The Norwegian Data inspectorate licensed 
the storage of research data in our institution, and permission to store biological material 
was granted by the Directorate of Health. All patients were informed of the study protocol 
in detail, and signed forms of consent prior to study participation. All participants were also 
informed of their right to withdraw from the study at any time.  
 
5. Results 
5.1 Paper I 
Our objective was to examine the cross-sectional associations between markers of 
inflammation, RA disease activity, medication used and NT-proBNP levels.  
In bivariate analyses, comparing the disease characteristics of patients with normal 
vs. elevated NT-proBNP, we found that these groups were comparable for all variables, 
except for CRP which was marginally increased in the group with elevated NT-proBNP. 
Patients who reported having a CVD at the 10-year follow-up had significantly higher levels 
of NT-proBNP at baseline and after 10 years. In the cross-sectional linear regression 
analyses of baseline and 10-year follow-up data, we found that CRP was a significant 
predictor of NT-proBNP levels in the multivariate models. At the 10-year follow-up, 
creatinine levels and disease duration were also associated with increasing NT-proBNP 
levels. 
We performed a mixed model repeated analyses adjusting for age and sex. In the 
univariate adjusted analyses several markers of disease activity were associated with NT-
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proBNP levels, but again in the final model only the presence of CVD and CRP remained 
significant. An increase of 10 years of age resulted in an increase of 25 % in NT-proBNP, 
while an increase of 10 mg/L CRP corresponded to an increase of 9% in NT proBNP levels.  
A longitudinal time variable was included in the model, and we found a significant trend of 
increasing NT-proBNP levels between baseline and the 10 year follow-up in the final 
model.  
5.2 Paper II 
In paper 2 we compared levels of CVD risk markers between patients with clinically active 
RA and RA in remission, and compared both these groups to community controls. 
Secondly, we compared CVD risk between patients with RA categorized according to anti-
CCP status, level of joint destruction and presence of extra-articular manifestations. 
The cohort consisted of 113 patients with RA and 86 community controls, all aged 
between 30 and 70 years. 82 patients were judged to have active RA (CDAI >2.8), whereas 
31 were in remission (CDAI ≤2.8). The community controls were significantly younger than 
patients in both RA groups, and were more often males than the patients with active RA. 
Patients with active disease had lower total cholesterol but higher CRP, lnNT-proBNP, 
brachial systolic pressure, AIx and central systolic pressure when compared to patients in 
remission and community controls in analyses adjusted for differences in age and sex. 
Additionally, RHI and lnPWV levels were both less favourable in patients with active RA 
than in patients in remission. 
Constructing a multivariate logistic regression model with active RA vs. RA in 
remission as the dependent variable, we found that some of the CVD risk markers, (RHI, 
lnPWV and AIx) were independently associated with having active RA. Patients with active 
RA were differentiated from those in remission with 96% sensitivity in age and sex adjusted 
models. The findings were verified by constructing a “case-control” cohort of 30 patients 
with active RA matched with a patient in remission of the same age and sex. Again we 
found that patients with active RA had higher lnPWV and AIx and lower total cholesterol 
and RHI when compared to patients in remission. Categorization of patients according to 
anti-CCP status, presence of extra-articular manifestation or level of joint destruction gave 
less consistent differentiations of CVD risk markers. 
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5.3 Paper III 
We examined the longitudinal impact of early inflammatory (RA) disease activity on 
measures of arterial stiffness in paper 3. At the 15-year follow-up of the EURIDISS cohort 
we recorded AIx and PWV in the participants. One hundred and two patients had acceptable 
recordings of AIx and 98 of PWV. The patients participating in the follow-up were younger, 
had less inflammation and better function at baseline than non-participants.  
In logistic regression analyses elevated baseline CRP predicted increased AIx and PWV 
(dependent variables in separate models) at the 15-year assessment in both the univariate 
and multivariate models. Current use of cholesterol-lowering drugs was an independent 
predictor of increased PWV (β (CI) 6.55 (1.12-34.44) p=0.045).  In linear regression 
analyses patients with elevated baseline CRP had significantly higher AIx (β (CI) 2.67 
(0.06-5.31) p=0.045) and lnPWV (dependent variables in separate models) after 15 years (β 
(CI) 0.08 (0.01-0.14) p=0.02) after adjustments for age, sex and mean arterial pressure. 
There was a trend of increasing AIx and PWV across quartiles of baseline CRP. These 
trends were however not significant (p=0.31) for AIx, nor for PWV (p=0.12).  
5.4 Paper IV 
In paper 4 we examined the incremental value of NT-proBNP in the prediction of mortality 
in RA across a panel of established and potentially novel risk factors. Established predictors 
for all-cause mortality in patients with RA are age, male sex, physical function, 
comorbidities and rheumatoid factor [2]. We chose to use the 1997 examination of the 
EURIDISS cohort as baseline, because some information on CVDs had been collected at 
this time-point. Of the 182 patients, 31 had died during the ten-year follow-up. As expected, 
the patients who had died were older, more often male, had a higher frequency of CVD-
related co-morbidities and poorer functional status (HAQ and NHP) at baseline. They also 
had higher baseline levels of DAS28, and NT-proBNP, CRP and ESR levels were 
borderline significantly increased in the patients who died in the follow-up period. 
Predictors of 10-year mortality were identified in univariate and multivariate 
logistical regression analyses. All models were adjusted for age and sex. We chose to 
examine how separate models performed by comparing prediction on an individual level. 
The number of patients included in each model varied due to missing data.  In the 
demographic model homozygous SE adjusted for age and sex correctly predicted 8 of 29 
deaths.  Amongst the variables of disease activity only DAS28 was a significant predictor 
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with a prediction of 10 out of 30 deaths. None of the co-morbidities were significant 
predictors at p ≤ 0.05, but a history of MI approached this level. The dichotomized variables 
reflecting health status; NHP and HAQ, were both significant in the adjusted analyses, but 
NHP was surpassed by HAQ in a multivariate “health status model “and lost significance. 
Elevated NHP adjusted for age and sex predicted 7 out of 27 deaths, whereas higher HAQ 
score predicted 16 out of 30. NT-proBNP was found to be an independent predictor in the 
“biomarker model” predicting 12 of 23 deaths.  
The final model included DAS28 and NT-proBNP and predicted 14 of 21 deaths and 
had thus a better sensitivity than the “health status model”. The receiver operator 
characteristics curves comparing the final model with the health status model showed that 
the combination of DAS28 and NT-proBNP had the greatest area under the curve although 
the CI were overlapping and the difference was thus not significant. 
5.5 Additional results- Biomarker validity 
The validity of biomarkers assessed depends upon the accuracy and precision of the 
measurements. The repeatability and reliability of the biomarkers used in the 15-year study 
were explored in the following ways: 
RHI: The test-retest reliability (repeatability) of the RHI measurements was assessed by 
examining 19 colleagues, (both male and female, aged 22-62) twice with a minimum 24 
hour period between the examinations. The average intra-reader correlation coefficient for 
two examiners was 0.84 (0.57-0.94). 
PWA: The reliability of PWA was partially verified by asking an experienced examiner to 
repeat the PWA examination in 19 of the included patients. The inter-reader correlation 
coefficient was 0.75 (0.51-0.90) for PWV and 0.96 (0.89-0.98) for the AIx. The PWA data-
selection procedure was shown to be highly repeatable when the author re-examined the 
original analysis two months after the first data-selection. New selections were made for 20 
patients, based on the same criteria, and the agreement between the first and the second 
selection was 0.94 (0.88-0.97) for PWV and 1.00 (0.99-1.00) for AIx. 
IMT:  The IMT measurements were made off-line using the AMS analysis software (Artery 
Measurement System, Thomas Gustavsson, Sweden). The method was found to be 
reproducible by comparing the measurements made by two examiners on images where the 
region of interest had been agreed upon. The inter-reader correlation coefficient for the 
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median IMT measurements was 0.99 (0.98-1.00). A Bland-Altman plot of the 
reproducibility of the measurements is presented in Figure 3.  
 
  
6. Discussion 
6.1 Methodology  
The following section is a critical appraisal of the validity of our methods. 
6.1.1. Patient selection 
The four papers included in this thesis present analyses of data collected from patients in the 
EURIDISS and ORAR cohorts. All patient data originate from patients examined at baseline 
and follow-up visits of these cohorts, and it is necessary to consider whether these patients 
are generally representative of patients with RA.  
  The external validity of the patients in the EURIDISS and ORAR cohorts can be 
assessed by comparing their disease characteristics to other cohorts [225]. The prospective 
Lund observational cohort was established in the late 1980s and included 183 patients with 
an average of 11 months symptom duration at baseline [227]. Patients were primarily 
recruited through primary care. The cohort was similar to the EURIDISS cohort with regard 
to average age at baseline, but included fewer women (64% vs. 74%). The major difference 
between these cohorts is apparent at the 10 year follow-ups when 74% of the Lund patients 
were RF positive compared to only 50% of patients in the EURIDISS cohort (IgM RF 
and/or IgARF). However, patients from all three cohorts (Lund, ORAR and EURIDISS) 
who had disease onset during roughly the same period were comparable with regard to 
health status (HAQ 1.1, 0.97 and 0.91 respectively) [227,228].  
The observed yearly all-cause mortality in EURIDISS cohort in the period 1997 to 
2007 was 1.7% which, although  somewhat  lower than the mortality reported in comparable 
cohorts [161] is within the confidence intervals reported in other studies [229]. The ORAR 
cohort is not readily compared to the EURIDISS cohort due to the differences in disease 
duration, but in the present data collection there were no statistical differences between 
patients in each cohort with regard to mean age, proportion of females, patients with IgM 
RF >25 U/ml, or mean current level of DAS28. The ORAR cohort has been extensively 
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validated for its completeness which is assumed to be 85% [11]. The high level of 
participation in the cohort vouches for the representativity of ORAR.  
The RA diagnosis of each patient included in the EURIDISS and ORAR cohorts was 
verified by a rheumatologist upon inclusion in the cohorts, and all patients were recruited in 
a hospital setting in the early-mid 1990s. The patients included in our analyses had a disease 
onset in the period 1988-1997. The current EULAR recommendation on the management of 
early arthritis recommends that the patient be referred to a rheumatologist within 6 weeks of 
symptom debut [28]. This recommendation was not in place at the start of this cohort and it 
is therefore possible that we have selected a group of patients who are at the more afflicted 
end of the RA spectrum, while patients less afflicted were treated by their general 
practioner.   
The patients in the EURIDISS and ORAR seem as a group to represent the milder 
end of the RA disease spectrum, although the great variance in level of inflammation and 
joint destruction in each cohort makes them very suitable for the identification of predictors. 
A potential selection bias may have been amplified due to the loss to follow-up which 
regularly occurs in longitudinal studies.  
6.1.2 Selection of community controls 
The community controls were asked to participate in the study after they had been identified 
by Statistics Norway. The community controls were significantly younger and more often 
male than the RA patients. These differences were largely explained by the fact that we had 
pooled the RA cohorts with a cohort of patients with ankylosing spondylitis (AS), and the 
AS patients were younger and more often male. This merge was done to allow for 
comparative studies of CVD risk in patients with AS at a later stage. Although the 
combination of two such different patient groups resulted in statistically significant 
differences in important demographic variables, the stratification did ensure that patients in 
each stratum had a number of controls to which they could be compared [230].  
The response rate of the community controls invited to participate in the study was 
43%, while 57% of the surviving members of the EURIDISS and ORAR agreed to 
participate at the 15- and 10-year follow-up, respectively. It is thus probable that a selection 
bias has occurred due to the high level of non-participation in the control population. This 
selection bias may have threatened the internal validity of our findings in paper 2 [225]. 
Members of the patient cohort may feel a certain loyalty to our hospital after consultations 
with the nurses and doctors at our department, and may have felt obliged to participate. The 
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community controls were specifically chosen due to their lack of previous rheumatic disease 
and had thus no feeling of loyalty to our department. 
The media and patient interest groups have informed their readers about the 
increased risk of CVD afflicting those with RA, and the patients participating in the 
examination could therefore partially have been motivated by self-interest. However, there 
are long waiting lists to see a cardiologist and a great awareness CVD risk in the community 
and our community controls could also have expected personal benefit.   We did not exclude 
individuals with a history of CVD from the community controls and did in fact observe that 
the RA patients in remission scored better in both the RHI and PWV when compared to the 
community controls, indicating that the latter group was not particularly healthy. A selection 
bias towards community control participation motivated by a personal fear of increased 
CVD risk would put us at risk of making a type II statistical error, i.e. being unable to 
identify differences between the populations. However, in paper 2 we did find clear 
statistically significant differences in the distribution of CVD risk markers between patients 
with active RA, and community controls. 
Analysis of the reason for the non-participation of community controls in case-
control studies indicated that age is an important factor, with lower rates of participation 
among young individuals. In general, a decline in the rate of participation in studies have 
been noted over the last decades across regardless of the age of the participants[231].  
6.1.3 Assessments  
The CVD risk markers utilized in the data collections were chosen in order to reflect the 
stages of the CV disease process from endothelial dysfunction to arteriolosclerosis and 
atherosclerosis. We assessed major confounders and ensured that we collected data 
necessary to calculate composite risk scores such as the Framingham. We considered FMD 
as a possible measure of endothelial function, but decided instead to use the Itamar because 
of time constraints. In addition to the data presented here, we have also assessed the 
prevalence of plaques in the carotid artery and performed echocardiographic examinations. 
Several other examinations could have yielded interesting data, but additional data on 
prevalent atherosclerosis, such as by assessing CAC would have been nicely complimentary 
to our data. 
The Sphygmocor device estimated the foot of the pulse wave using intersecting tangents. 
The Complior (Fukuda Denshi Co., Ltd.,Tokyo, Japan) is another popular device for 
estimating pulse wave velocity. The Complior registers concurrent pulse waves at carotid 
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and femoral sites using mechano tranducers [127]. The software of the Complior then 
estimates the points of maximal rate of change on the pressure wave forms and uses the 
correlation between these points to calculate the speed of the pulse wave [232]. A study 
comparing the Sphygmocor with the Complior found that the latter device estimated 
significantly higher values of PWV than the Sphygmocor [232].  
When choosing measures of RA disease activity and function we were very much 
influenced by previous data collections, which permitted comparison of disease state 
between different examinations and time-points. The ACR “Core set of disease activity 
measures for RA clinical trials” has described the variables that should be assessed in 
clinical trials, and our data collection was performed in accordance with this consensus 
[233]. Joint destruction, a measure of cumulative disease activity, was assessed by 
conventional x-ray. We would clearly have wished to examine the joints of the hand and 
wrist with ultrasonography and magnetic resonance imaging to better define RA disease 
remission [234], but again it was considered too time consuming for the participants.   
Bone mineral density was measured in participants for later analyses of the 
association between osteoporosis and CVD. We considered using the apparatus to assess 
body composition, but decided against prolonging the burden on the patients. 
There are several possible sources of biomarker inaccuracy which would threaten the 
validity of our findings. In planning the studies we acknowledged that inaccuracy was an 
inherent fact in any study and attempted to ensure that any bias was distributed at random.  
All participants were examined in the afternoon and all received the same written 
information. The staff were encouraged to remain at the same “station” each week.  All 
arterial stiffness measurements were performed by a single examiner.                                    
In the following I will present some of the factors that may have impacted on the results:.  
 
Preanalytical variability 
Measures of endothelial function, blood pressure and PWV display diurnal variations. 
Whereas endothelial function is reduced in the early morning, the pressure measurements 
and PWV reach their peak in the evening in patients with essential hypertension [235]. The 
assessments in the current studies were all performed in the same room and at the same time 
of day. All patients and controls received the same information regarding the examinations 
which were to be carried out and were asked to abstain from food, cigarettes and alcohol for 
three hours prior to the examination. Ideally, the studies should have been carried out after 
an overnight fast with controls and patients being examined at the same session, but this 
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ideal situation was not possible due to logistical and feasibility limitations. We used the 
examination rooms of our out-patient department in the late afternoon, after regular 
appointment hours, and could not ask our participants to fast all day.  The recommendation 
of at least a 3 hour fast prior to examinations of arterial stiffness was advocated by the 
expert consensus of arterial stiffness measurements [127], while the RHI is ideally 
performed after an overnight fast [120]. After observing that the logistics of the data 
collection worked well, we started to include control subjects in our study 
A key determinant of PWV is of course how the distance travelled by the pulse wave 
during the transit time is estimated. Like many other groups using the Sphygmocor device 
[236,237], we chose to measure the distance travelled by subtracting the distance from the 
supra-sternal notch to the carotid site from the distance between the supra-sternal notch and 
the femoral site. This is the method that is recommended by the manufacturers [220]. 
However, the majority of survival studies have measured the distance in a straight line 
between the carotid and femoral sites [136,143,144]. The recent published “Reference 
Values for Arterial Stiffness Collaboration” chose to convert all distances measured into 
direct measurements using a validated conversion equation [238]. Weber et al compared 
values of the PWV calculated from five different methods of wave travel estimation, to 
invasively measured PWV, and concluded that the subtraction method chosen in our study 
gave the most accurate estimate. However, all methods showed an acceptable correlation to 
the invasively measured PWV (Spearmann’s R: 0.73-0.77). A comparison of four of these 
methods revealed a disparity of 16-31% between PWV estimates, although the correlation 
between methods was very good (Pearson’s R 0.97-0.99) [239]. The method used in our 
studies gave the lowest PWV of the four methods. Accordingly, the 12 m/s cut-off point for 
PWV recommended by the ESC/European Society of Hypertension guidelines corresponds 
to a PWV of 8.3 -10.6 m/s by the methods used in our studies[232,239].  
 Another possible source of error in the estimation of distance travelled is due to 
central obesity, which may stretch the tape measure over the abdomen. Callipers can be 
used to overcome this problem [239].  Even though the BMI of the patients and controls 
(mean value 26.1 vs. 25.4) was comparable (student t-test p=0.29) we cannot rule out that 
we have overestimated the distance in a few obese patients, and thus overestimated the 
PWV in these patients. 
Ethnicity may be another source of pre-analytical variation [240]. We did not make 
any formal registration of ethnic origin but observed that the vast majority of individuals in 
the ORAR and EURIDISS cohort follow-up were of Norwegian origin. Statistics Norway 
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chose participants for the community controls at random and patients with non-Norwegian 
sounding names were also asked to participate. However, the individuals who chose to 
respond positively to the invitation were also mainly of Norwegian origin.  
A recent study found that brachial and central blood pressures were reduced in the 
late follicular phase of the menstrual cycle when the FMD was at its greatest [241]. We 
were not able to time our examinations according to the menstrual cycle of our female 
participants but this source of variability should be randomly distributed amongst patients 
and controls.  
Strengths and limitations of the statistical method 
It is known that age impacts differentially on blood pressures, PWV and AIx. The large 
Anglo-Cardiff Collaborative Trial with 4001 participants found that in contrast to the 
systolic blood pressure which increased steadily with progressive aging, the diastolic 
pressure peaked at around 50 years and then declined [242]. In the same study, the rate of 
increase in AIx was similarly shown to decrease after the age of 50 and the linear regression 
equation describing the association between age and AIx included a negative age squared 
(age²) term. The relationship between age and PWV on the other hand included a positive 
age² term, illustrated by an acceleration of the rate of increase across the age groups. These 
finding are similar to those reported in participants of the Framingham heart study [237].  
We have not included polynomial regressions in our analyses, except for an attempt 
at improved model fitting in paper 2. An alternative approach would be to analyse patients 
aged < 50 and ≥ 50 years in separate analyses but this was prohibited due to insufficient 
numbers.  
6.2 Main results 
6.2.1 The cross-sectional association between markers of RA disease activity and 
markers of CVD risk (paper 1 and paper 2) 
Paper 1 and 2 are both cross-sectional in design and examine the relationship between RA 
disease activity and markers of CVD risk. In order to understand the significance of our 
findings, it is necessary not only to consider the possible impact of inflammation on CVD 
risk markers, but also to explore the relationship between the markers used in the studies. 
We found significant repeated cross-sectional associations between CRP and levels of NT-
proBNP in the EURIDISS cohort (paper 1). CRP remained independently associated to NT-
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proBNP levels even after controlling for known cardiovascular risk factors and the presence 
of self-reported CVD at the 10-year follow-up. These findings have later been replicated by 
several authors and levels of NT-proBNP have also been shown to be reduced by treatment 
with TNF-α inhibition [243,244]. In paper 2 we again found that NT-proBNP levels were 
associated with RA inflammatory disease activity; as patients with active RA had higher 
levels of NT-proBNP than patients in remission. 
 The association between NT-proBNP and markers of inflammation may have several 
potential explanations. A very interesting paper from the field of cellular biology came to 
our attention after the publication of the first paper. Ma et al showed that exposing murine 
cardiocytes to inflammatory cytokines such as IL-1 β and TNF-α resulted in a dose-
dependent increase in BNP levels [98]. Similar findings are also reported from experiments 
on canine cardiac fibroblasts, where BNP release was augmented by TNF-α [245]. The 
association between inflammation and NT-proBNP levels could plausibly also be related to 
increased arterial stiffness. A finding in paper 2 was that patients with active RA had higher 
AIx and PWV than patients in remission. PWV is an independent  determinant of BNP 
levels in models that adjust for left ventricular ejection fraction [246] and NT-proBNP 
levels have also been found to be associated with PWV in the Framingham Heart Study 
[247]. A more recent study by Schroff et al reported that arterial stiffness was determined by 
BNP and CRP levels and suggests that the increased cardiac afterload caused by heightened 
arterial stiffness could be an explanatory factor. The process of arterial stiffening will 
increase the speed of the reflected pulse wave, resulting in increased central systolic 
pressure and ventricular hypertrophy, while reducing the blood flow in the coronary arteries 
during diastole [133,246]. BNP is released as a consequence of stretching the atrial and 
ventricular wall and acts through natriuresis to reduce the blood volume while modulating 
ventricular remodelling [92]. Increased levels of inflammatory markers are, as already 
mentioned, associated with an increased risk of CV morbidity and mortality in the general 
population and in patient with RA [64-66,83,85], and flares in disease activity have 
specifically been linked to the initiation of CHF in RA[168]. 
 The process of ageing naturally entails the stiffening of arteries, but several authors 
also find that inflammation generates an accelerated increase in arterial stiffness [236,248-
250]. There are several theories to explain the connection. Vlachopoulos et al found that a 
vaccination against Salmonelle typhi brought about a short-lived increase in PWV. The 
authors postulated that matrix metalloproteinases, which also increased subsequent to the 
vaccination, may cause structural and functional changes in the aortic wall thereby 
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increasing the aortic stiffness [251].  Another possible mechanism involves inflammatory 
cytokines which have been shown to up-regulate angiotensin type 1 receptors causing 
vasoconstriction and hypertension which subsequently may lead to arterial stiffness [54,90]. 
If we accept arterial stiffness to be a result of both structural and muscular properties of the 
artery wall, then the interactions between inflammatory markers and the arterial wall may 
have several modes of action. The net result, as presented by the expert consensus on 
arterial stiffness, is that inflammation may accelerate the process of arterial stiffening by 
increased vascular collagen formation, calcification and breakdown of elastin [127].   
  In paper 2, the RHI was reduced in patients with active RA, indicating a diminished 
endothelial function. The endothelium injury model is indeed often mentioned as a 
mechanism of arterial stiffness development. An  injury to the endothelium  heralds the start 
of intimal thickening, with a decrease in vascular wall contractile elements as smooth 
muscle cells migrate to the intima, multiply and lay down extra-cellular matrix [36]. In other 
studies NO has been shown to be an important regulator of arterial stiffness, possibly 
through the up-regulation of endogenous vasodilators [252-254].  NO release is mediated by 
the endothelium and may be blighted by inflammation [89,254,255].  However, although 
some studies have found cross-sectional and longitudinal associations between 
inflammation and endothelial dysfunction in patients with RA [191,193], this finding is 
contradicted by others [256]. In the general population CRP levels appear not to be related 
to the FMD [257], although reactive hyperemia may be related to inflammation [258] 
 Arterial stiffness was found to be more closely related to both peripheral and central 
systolic pressure than measures of atherosclerosis in paper 2. PWV, AIx, peripheral and 
central systolic pressure were all significantly higher in patients with active RA compared to 
patients in remission. The relationship between arterial stiffness and hypertension displays a 
complex circular nature. Arterial stiffness is a predictor for the development of 
hypertension, while high pressures act on the vessel wall to cause increased stiffening 
[259,260]. The longitudinal Caerphilly study found that the cumulative heart rate x PP 
product predicted PWV levels later in life, illustrating how repeated stress on the vascular 
wall could promote increased stiffness [261].  A review by Cecelja and Chowienczyk 
concluded that age and blood pressure, rather than other classical risk factors for 
atherosclerosis such as cholesterol, were the principal determinants of cfPWV [260]. 
However, both AIx and PWV have been shown to be associated with the presence of 
coronary artery disease in cross-sectional studies on diverse populations, and hypertension 
is also a powerful predictor of CVD [135,136,138,262]. The relationship between arterial 
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stiffness and atherosclerosis is currently under debate [263] and while PWV has also been 
shown to correlate with the amount of atherosclerosis in an autopsy study, the strength of 
the association was weak [264]. 
 IMT, a measure of atherosclerosis, was not found to be increased in patients with 
active RA (paper 2), although many other studies have found increased IMT in patients with 
RA, even within the first year of RA disease activity [265,266]. Indeed, as noted above, 
IMT and plaque have both been found to be cross-sectionally related to measures of 
inflammation [208], although a small recent study did not find that IMT was associated to 
CRP levels in 59 patients with RA [256].  
As previously mentioned, a negative correlation has been reported between markers 
of inflammation and total cholesterol [175], and it has been suggested that the reduced total 
cholesterol in patients with RA is largely driven by a fall in HDL [171,172]. In the sub-
analysis of the Apolipoprotein-related MOrtality Risk (AMORIS study), patients with RA 
were found to have significantly lower total and non-HDL cholesterol than participants 
without RA[178].  In paper 2 we found lower total cholesterol in patients with active RA 
compared to RA in remission and community controls. The HDL levels and atherogenic 
index did not differ significantly between the groups, but HDL was numerically higher in 
the community controls. The finding of lower total cholesterol in association with active RA 
may confuse the clinician wishing to prevent CVD in patients with RA. The recently 
published paper by Peters et al, gives beautiful illustrations of the negative correlations of 
both total cholesterol and HDL with CRP levels in a cohort of patients with RA. The impact 
of inflammation appears to have a greater effect on HDL than total cholesterol, resulting in 
a positive correlation between atherogenic index (total cholesterol/HDL) and CRP. Indeed, 
the atherogenic index, not total cholesterol, predicted CV events in this study, and the 
authors argue that the index should be used when assessing CVD risk in patients with RA 
[267]. 
In paper 2, patients with active RA did not have higher Framingham risk score 
compared to patients in remission and community controls. Despite exhibiting higher 
systolic blood pressures, this group also had lower total cholesterol which will have 
contributed towards a lower risk score. The European SCORE risk calculator [1] was 
elevated for the active RA patients when compared to patients in remission, and this could 
be due to a greater contribution of blood pressure measurements in this estimation or due to 
the difference in outcome.  
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The results presented in paper 1 and 2 indicate that achieving disease remission in 
RA may reduce cardiovascular morbidity. The studies were cross-sectional in design and we 
are therefore restricted to making predictions regarding future incidence of CVD. However, 
the biomarkers used in our studies have all been validated as independent predictors of 
incident CV events. As previously mentioned, treating RA disease activity with a range of 
medication from hydroxycholoroquine to biologics, may have beneficial side-effects on the 
lipid profile due to the increase in HDL [183,186].  Several studies had reported on the 
improvement of endothelial function under treatment with TNF-α inhibitiors prior to the 
start of this thesis, and these findings have again been confirmed, albeit in small studies 
[268], and repeated in patients treated with rituximab, a novel biologics targeting CD20 
cells [269]. Indeed, numerous studies have shown attenuated CVD risk as a consequence of 
TNF-α inhibition in patients with RA. Peters et al have shown that treatment with 
adalimumab significantly reduced NT-proBNP levels after 16-weeks in 171 patients with 
RA [244]. Blood pressure was reduced in the group randomized to receive infliximab under 
the BeSt study [270]. Furthermore, several studies find that TNF-α inhibition will reduce 
PWV in patients with RA [236,271,272], for a period of up to 56 weeks [273]. Some have 
also reported improved AIx under treatment with etanercept [274], although this particular 
finding is disputed [236,272,275]. IMT has also been reported to decrease during TNF-α 
inhibition [276], while other authors report IMT to be unchanged after a year of treatment 
[273]. A study by Del Porto et al points in a direction that is very relevant to our findings. 
They divided patients into 2 groups according to response to TNF-α inhibition, and found 
that the group with the best response (≥ACR 20 response maintained during a year) 
exhibited a reduction in IMT, while the other group did not [277]. This distinction is also 
made in a study by Dixon et al, which reported a decreased MI rate in patients showing a 
EULAR moderate or good response on TNF-α inhibition [278].  
The use of DMARD, TNF-α inhibitors and prednisolone was restricted to the patient 
groups in our cohorts. We could therefore not examine these drugs as confounders of the 
differential CVD risk between patients and controls. Furthermore, channelling bias may 
entail that patients with high disease activity were more likely to be given certain 
medications than patients in remission, and we could not adjust for this in the cross-
sectional analyses when comparing CVD risk between patients with active RA and RA in 
remission. Our solution was to examine the use of these different medications as possible 
confounders of the distribution of CVD risk between patients with active RA and RA in 
remission.  
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Arguably the strongest evidence on the benefits of treating RA disease activity 
comes from studies looking at “hard” clinical end-points such as MI, CV events and 
mortality. An early study by Choi et al, reported reduced CVD mortality in patients treated 
with MTX [279], although Landewé et al reported conflicting results [280]. Even earlier, 
Krause et al reported that response to MTX treatment was associated with a reduced general 
mortality in patients with RA [281]. More recent studies from Sweden have found reduced 
CV events and general mortality in patients treated with TNF-α inhibition [282,283]. 
Provocatively there are indications that treatment with any DMARD [284], over a 
sufficiently long period [285] reduces CVD risk, although the fact that the medication is 
continued by the treating physician does suggest that the drug has some beneficial effect on 
disease activity.  
As previously mentioned, the treatment of patients with RA has changed radically 
over the past decade. The focus is now on early, intensive therapy in order to achieve 
remission [33]. The recently published recommendations of an international expert 
committee have conceptualized the new paradigm as “treat to target” (T2T). The “target” in 
T2T is clinical remission, and the consensus advocates “abrogation” of inflammation as 
necessary to preserve physical function. In order to achieve and sustain remission, frequent 
assessments of disease activity using a composite activity score is recommended [286].    
6.2.2 A comparison of CVD risk markers in patients with RA and community 
controls (paper 2) 
In paper 2 patients with active RA were found to have higher NT-proBNP, peripheral and 
central systolic pressure and AIx than community controls, suggesting that the patients with 
RA had a higher CVD risk. The patient group was older and more often female, and we 
adjusted for these differences in the regression models. While patients with RA by the very 
nature of the disease have higher levels of inflammation than community controls, there are 
many additional reasons for the unfavourable CVD risk status of patients with RA.  
We explored BMI, smoking habits, co-morbidities and current medication as possible 
confounders of the final outcome, although it is impossible to adequately adjust for the 
cumulative exposure to these confounding risk factors in a cross-sectional study.  
There were no significant differences in BMI between patients and controls in paper 
2. Furthermore, the BMI did not confound the results of our analyses.  Two large cohorts 
have reported that low BMI is associated with increased mortality in this group [287,288]. 
One of these papers estimated a reduced risk of death of 9% for each unit increase of the 
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BMI, and reported lowest mortality for patients with a BMI ≥ 30 kg/m² [288]. In studies on 
patients with CHD, a U-shaped relationship between BMI and risk of mortality has been 
noted [289]. Low BMI can be a sign of high inflammatory disease activity in patients with 
RA, but may also indicate co-morbidities that may by them self confer an excess risk of 
death. Adjusting for disease activity and co-morbidities in this study ameliorated the 
negative effect of a low BMI on risk of death [288]. Even though our patients had BMI 
values that were comparable to the controls, current knowledge suggests that they may have 
had an abnormal body composition, with increase fat mass and reduced muscle volume 
[290].  It is therefore a limitation that we do not have data on body composition in our 
study.  
The frequency of smokers (ever vs. never) did not differ significantly between 
patients with RA and controls in our study. Solomon et al reported a greater frequency of 
past and present smokers in women with RA, whereas Del Rincon et al did not find 
significant differences between RA patients and controls [176,195].  As previously 
mentioned, smoking has in recent years been identified as a probable key player in the 
pathogenesis of RA[21], and knowledge of this fact may have influenced the RA patient’s 
smoking habits. We did not have sufficient data to pin point the time of smoking cessation 
and decided to treat smoking as “ever vs. never”. In light of current literature it is surprising 
that smoking was not a confounder of the CVD risk markers in our study [291].  
NSAIDs are also possible confounders of CVD risk, and NSAID exposure will be 
related both to the level of RA disease activity and to CVD risk. The detrimental role of 
NSAID and COXIB medication in the development of CVD is by now well established after 
the first analyses of data from the APPROVe (Adenomatous Polyp Prevention On Vioxx) 
trial [292]. Performing a meta-analyses of 121 placebo controlled trials, Kearney et al found 
that use of both NSAIDs or COXIB was associated with an increased risk of MI [293]. 
NSAID and COXIBS, with the possible exception of naproxen, are thought to cause 
thromboembolic events through the cyclo-oxygenase-2 mediated inhibition of prostaglandin 
I2, allowing tromboxane-A to act unopposed in causing platelet aggregation and 
vasoconstriction [294].  Use of NSAIDs at baseline was not associated with increased AIx 
and PWV after 15 years in paper 3, but we unfortunately did not have reliable data on 
cumulative use of NSAIDs.  In a small, randomized and placebo controlled study Wong et 
al failed to find any negative effect on endothelial function or AIx following a 2 week 
course of Indomethacin [295]. Interestingly, a longitudinal study from the NOAR (Norfolk 
Arthritis Register) found that use of NSAIDs at baseline was a protective factor, reducing 
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the risk of a future CVD event. The authors suggest that this may be due to a “healthy user” 
effect, indicating that rheumatologists are assessing the patient’s CVD risk prior to 
prescribing this medication [296]. Naproxcinod is the first in a new class of anti-
inflammatory drugs which are labelled “Cyclooxygenase-Inhibiting Nitric Oxide-
Donating”. This drug becomes metabolized into Naproxen and NO, and the hope is that the 
NO will counteract the hypertensive effect of Naproxen by regulating vascular tone, by 
increasing mucosal blood flow and mucous production to protect the gastrointestinal 
tract[297]. The United States Food and Drug Administration (FDA) has requested further 
trials of long-term follow-up, but a recently published double blind randomized placebo 
controlled trial in 810 patients with only a 13 week follow-up, does suggest that the drug has 
a negligible effect on blood pressure, while giving pain relief similar to that of Naproxen 
[297]. 
Physical activity is another possible confounder of the outcome and was regrettably 
not assessed in the 15-year EURIDISS/10-year ORAR data collection. Solomon et al found 
that women with RA were less physically active than their age and sex matched controls, 
and that the level of physical activity was related to RA disease activity [5]. Physical 
activity is related to a favourable CVD risk profile in patients with RA even after 
adjustments for disease activity and health status [298].  
6.2.3 Longitudinal associations between RA disease activity and CVD risk 
markers (paper 3) 
We reported that elevated inflammation early in the RA disease course is independently 
associated with increased AIx and PWV after 15 years in paper 3. Population studies have 
found that 10 years aging corresponds to an increase in PWV of 0.48 m/s in a young adult 
male, and 1.36 m/s in an elderly male [242]. A baseline CRP above the median predicted an 
increase in later PWV of 1.1 m/s in our study, a level of change that could potentially be 
clinically significant. As previously mentioned, an association between early inflammation 
and CV mortality has been identified in patients with RA [64]. Interestingly cumulative 
inflammation has also been shown to correlate with future AIx in two small studies of 
patients with long-standing RA [249,299], whereas PWV has been found to be cross-
sectionally related to CRP in other studies [271]. 
Recently published data from the Caerphilly study confirm our findings in a large 
population drawn cohort of 825 individuals. Mc Eniery et al demonstrated that CRP levels 
at baseline were important determinants of AIx and PWV measured 20-25 years later. CRP 
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was also cross-sectionally associated with both PWV and AIx. This paper discusses the 
possibility of reverse causation to explain the findings whereby the arterial stiffness would 
be a factor causing elevated inflammation, possibly through damage to the arterial wall 
caused by the elevated PP that is secondary to increased arterial stiffness [261]. Our findings 
suggest that the chain of events could be in the opposite direction as inflammation measured 
in patients with RA is dominated by arthritic inflammatory activity [84], and inflammation 
caused by irritation of the vascular wall is in this context very minor [46]. 
If arterial stiffness in patients with a chronic inflammatory disease is partly 
determined by early and cumulative inflammation during the disease course, then early and 
aggressively targeted therapy could potentially reduce future CV morbidity and mortality in 
these patients. Targeting disease activity with disease modifying anti-rheumatic drugs 
(DMARD) therapy within the first year after an RA diagnosis has indeed been found to 
reduce IMT and improve the atherogenic index, indicating a reduced risk of future CVD 
[266]. The recently published ACR/EULAR collaborative RA diagnostic criteria enable the 
clinician to diagnose RA at an earlier stage in the disease course, by excluding the presence 
of conventional x-ray erosions from the diagnostic algorithm [300]. Indeed, a patient 
presenting with multiple synovitis, elevated markers of inflammation and positive serology, 
will qualify for the RA diagnoses before 6-weeks of disease duration, provided alternative 
causes of clinical synovitis are considered unlikely [300].  
6.2.4 NT-proBNP as a predictor of general mortality in patients with RA (paper 
4) 
Our results show that NT-proBNP is an independent predictor of 10-year mortality in this 
cohort of patients with longstanding RA. Established risk factors for RA mortality were also 
significant predictors in our cohort and the HAQ score, adjusted for age and sex, had the 
highest single variable discriminatory power. The validation of CV risk markers in patients 
with RA is important, but to our knowledge few studies have hitherto focused on this [301]. 
Variables reflecting RA disease activity can be grouped into two clusters, the 
variables in each cluster being mutually closely correlated. One cluster includes variables 
that describe patient centred outcomes; these may be derived from patient self-reported 
questionnaires of which the HAQ score is an example. The other cluster includes measures 
of RA disease centred outcomes such as ESR, CRP, RF factor and radiographic joint 
erosions.  In general the patient centred outcomes are reported to be better predictors of 
mortality than the disease centred variables [2], although they, to our knowledge, have not 
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previously been compared to SE or NT-proBNP. NT-proBNP as a single variable (adjusted 
for age and sex) had approximately the same predictive ability as the HAQ score. The final 
model that included DAS28 was superior to other models, although the confidence intervals 
(CI)s of the ROC curves were not significantly different. A recent study from the 
CORRONA registry found that the risk of ischemic events in RA was best explained by a 
model which included variables of RA severity as well as traditional CVD risk factors 
[302], although variables of RA severity seemed to have a slightly higher C-statistics for 
predicting the outcome, than traditional CVD risk factors.  
NT-proBNP is known to correlate with ventricular function in patients with CHF but 
is then increased to much higher levels than those seen in populations without clinical CVD. 
This biomarker has also become an important screening tool detecting pulmonary arterial 
hypertension in patients with systemic sclerosis [303].  A study by Bibbins-Domingo et al 
on patients with stable coronary heart disease is intriguing as it demonstrated the 
independent contribution of NT-proBNP levels to the prediction of both general, and CVD 
mortality, in models that adjust for echocardiographic data and level of inflammation 
[304,305].  
6.2.5 Biomarker validation 
Biomarkers reflecting CVD risk and RA disease activity are integral to the framework of 
this thesis. Biomarkers have the potential to fulfil many roles, from being predictors, 
indicators of disease diagnosis or stage, to prognosticating on future events. This is what 
makes a biomarker so attractive and why there is a continual drive to launch new candidates 
on the market [61]. Researchers from the field of cardiovascular medicine and rheumatology 
have sought common inspiration from the work of The National Institutes of Health (NIH) 
Biomarkers Definition Working group in developing parallel frameworks for biomarker 
validation [58]. Both frameworks demand that biomarkers employed in clinical medicine 
must fulfil demands of accuracy, sensitivity to change and display high repeatability and 
reproducibility [60,61]. Rheumatologists have conceptualized biomarker validation in the 
OMERACT (Outcome Measures in Rheumatology) filter in the field of rheumatology. The 
biomarker must satisfy the filters of truth (face, content, constructs and criterion validity), 
discrimination and feasibility in order to be acceptable [306,307]. Once a biomarker has 
been validated, it may come under consideration as a surrogate end-point, and potentially 
the substitute for a specific clinical end-point in a trial [60,61,308]. A formalized surrogacy 
ranking scheme has also been developed by OMERACT, ranking biomarkers according to 
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available studies showing a biomarker relationship to clinical target, rating the study design 
and the statistical strength of the findings [60,309].  
Several of the CVD risk markers studied in this thesis have been validated as 
surrogate end points of clinical CVD disease and some are accepted as surrogate end point 
in clinical trials by the FDA[310]. A PWV >12m/s is as previously mentioned, accepted as 
evidence of target organ damage according to the ESC, although as discussed, this level 
should probably be lower for the Sphygmocor [1,232]. Papers 3 reporting that CRP is a 
longitudinal predictor of elevated PWV could therefore be viewed as a study contributing to 
the validation of CRP as a biomarker of target organ damage. However, the study suffers 
from lack of baseline information on important and probable confounders such as lipids, and 
the findings must be validated in other longitudinal cohorts. Paper 4 reports that NT-
proBNP is a predictor of general mortality in a 10-year follow-up study, and as death is the 
most highly ranked patients-centred outcome this study would rate highly in the Target 
domain. There is however again an unfortunate lack of information on important 
confounders at baseline which would give a lower score for study design.  
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7.  Conclusions  
7.1 Main conclusions 
On initiating this work we posed several specific research questions. We can now 
summarize the following answers to the main research questions:  
 
1. Are markers of CVD risk and RA disease activity cross-sectionally associated? 
 CRP is cross-sectionally associated with levels of NT-proBNP and remained an 
independent predictor of NT-proBNP levels after controlling for known cardiovascular risk 
factors and the presence of self-reported CVD 
 CDAI levels indicating active RA disease were associated with significantly higher 
levels of NT-proBNP, brachial systolic pressure, PWV, AIx and central systolic pressure as 
well as poorer endothelial function when compared to patients in RA remission, but also 
with lower cholesterol levels.  
 
2. Do biomarkers of CVD risk differ between patients with RA and community 
controls? 
 Patients with active RA had significantly higher levels of NT-proBNP, brachial 
systolic pressure, AIx and central systolic pressure, but lower cholesterol when compared to 
community controls.  
 
3. Is there a longitudinal association between RA disease activity and markers of CVD 
risk? 
 Elevated inflammation, measured by CRP early in the RA disease course, was 
independently associated with increased AIx and PWV after 15 years.  
 
4. Do levels of NT-proBNP predict general mortality in patients with RA and how does 
this biomarker compare to known predictors of mortality in RA? 
 NT-proBNP was an independent predictor of 10-year mortality in this cohort of 
patients with longstanding RA. Established risk factors for RA mortality were also 
significant predictors in our cohort. The HAQ score, adjusted for age and sex, had the 
highest single variable discriminatory power, but an age and sex model of NT-proBNP and 
DAS28 scores gave the best prediction. 
 62
 7.2 Future research opportunities 
The data collection that was initiated at the start of this thesis, the 15-year EURIDISS and 
the 10-year ORAR, and finally the establishment of a community cohort, will hopefully in 
the future answer other research questions than the ones presented in this thesis. 
The data collected should give us the opportunity to validate our CVD risk markers 
as predictors of CV related mortality within a 5-7 year perspective. All participants have 
signed consent forms which will allow us to merge the cohort data with data from the 
Norwegian death register.  
We have taken advantage of the skills developed by ourselves and by other staff 
during the data collections to plan similar examinations in cohorts of patients with 
ankylosing spondylitis and osteoarthritis. In this work we have liaised closely with several 
physiotherapists to ensure that physical activity and fitness are surveyed in these patients 
groups. 
7.3 Clinical implications and future perspectives 
If we are to effectively prevent cardiovascular events in patients with RA, we must identify 
RA disease characteristics which signal an increased risk of CVD. Identification of patients 
at high risk will support an effective individualized strategy of targeted therapy. Our studies 
indicate that patients with active RA disease qualify for intensified action in order to prevent 
future CV events. Of the CVD risk markers measured in these papers brachial systolic 
pressures is probably the marker most amenable to modification. The EULAR 
recommendations of CVD risk management recommend an annual screening of CVD risk in 
patients with RA [311].  
CVD risk management in patients with RA should be implemented according to the 
national guidelines [311]. The possibility of pleiotropic treatments may open up new 
treatment options. Angiotensin-converting enzyme (ACE) inhibitors and statins have been 
shown to improve the endothelial function of patients with RA [312,313]. The TARA study 
further reported on the pleiotropic effects of statins by showing a small but significant 
reduction in RA disease activity in addition to lipid lowering following treatment with 
atorvastatin [314]. The future could hold new paradigms of CVD risk control during flares 
in RA disease activity as a matter of course, with a subsequent alleviation in risk control 
during states of disease remission.  
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Whether the general practioner or the rheumatologist should be responsible for assessing 
and treating the CVD risk factors and instigating the treatment is beyond the scope of this 
thesis to decide. This study has revealed an unmet need in CVD risk management, a need 
that is also evident in other contexts [315,316]. The association between active RA disease 
and increased levels of CVD risk markers discussed in this thesis underscores that the 
rheumatologist may indirectly modify CVD risk by the aggressive treatment of RA [317]. 
We hold in our hands weapons which have been proven to reduce CVD risk and their proper 
use depends upon the vigilance of the rheumatologist. 
 
8. Figures and Tables 
Figure 1 Characteristics of the people who tend to stay healthy [1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. No smoking 
2. Healthy food choices 
3. Physical activity; 30 minutes moderate activity daily 
4. BMI < 25 kg/m² and avoidance of central obesity 
5. Blood pressure <140/90 mmHg 
6. Total cholesterol < 5 mmol/L 
7. LDL cholesterol < 3 mml/L 
8. Blood glucose < 6 mml/L 
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Figure 2   The pulse wave. 
 
Permission to reprint has been granted [318] 
T0 ; time at start of waveform, T1;  duration from start until first peak of outgoing pressure 
wave, T2; duration from start until second peak (reflected pressure wave), ED; ejection 
duration, SP; Central aortic systolic pressure, DP; central aortic diastolic pressure, P1; 
height difference between the minimum pressure and pressure at the first peak (T1), ΔP; 
augmentation, (difference between maximal pressure (SP) and pressure at first peak(T1)), 
PP1; pulse pressure, AIx; augmentation index. 
 
 
 
Figure 3 A Bland-Altman plot showing reproducibility of IMT measurements.  
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Table 1 Papers concerning the AIx in patients with RA 
 
 
Authors Cohort Design Finding 
Klocke[198]  14 patients with RA and no 
CVD, and 14 healthy controls.  
Cross-sectional AIx increased in RA. 
Mäki-
Petäjä[236] 
77 patients with RA and 142 
controls. RA patients 
commenced treatment with 
etanercept. 
Cross-sectional 
and longitudinal 
AIx was not increased in RA 
and was not altered by 
treatment 
Avalos[319] 117 patients with RA and 65 
healthy controls. 
Cross-sectional AIx increased in RA. 
Pieringer[320]  36 patients with RA with 36 age 
and sex matched controls.  
Cross-sectional AIx increased in RA. 
Wong M[273] 26 patients with RA who 
commenced treatment with 
infliximab.  
Longitudinal AIx unchanged by treatment. 
Wållberg-
Jonsson[299] 
30 patients with RA and 30 
controls. Calculated 
retrospective inflammation score 
Cross-sectional  AIx increased in RA and 
levels correlated with a 
retrospective inflammation 
score. 
Galarraga[274] 148 patients with RA of which 
21 commenced MTX treatment 
and 26 etanercept treatment. 
Cross-sectional 
and longitudinal 
AIx increased in patients with 
CRP>10 mg/l and was 
reduced by treatment with 
etanercept not MTX 
Crilly[249] 114 patients with RA and no 
CVD. Calculated cumulated 
ESR 
Cross-sectional Increased AIx correlated with 
cumulated ESR. 
Angel[275] 35 patients with RA and other 
rheumatic disorders commencing 
treatment with TNF-α inhibitors. 
Cross-sectional 
and longitudinal 
AIx unchanged by TNF-α 
inhibitions. 
Crilly[321] 114 patients with RA and no 
CVD 
Cross-sectional AIx correlated with HAQ and 
number of damaged joints. 
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Table 2 Papers concerning PWV in patients with RA 
Author Cohort Design Finding 
Yildiz [199] 8 patients with RA  Cross-sectional PWV increased in 
RA 
Mäki-Petäjä[236] 77 patients with RA 
and 142 controls. 
RA patients 
commenced 
treatment with 
Enbrel® (etanercept) 
Cross-sectional and 
longitudinal 
PWV increased in 
RA, associated with 
CRP levels and 
reduced by 
treatment.  
Wong M[273] 26 patients with RA 
who commenced 
treatment with 
Remicade® 
(infliximab).  
Longitudinal PWV reduced by 
treatment 
Stamatelopoulos[322] 84 pasients with RA 
and 84 controls. 
Cross-sectional PWV increased in 
RA and correlated 
with disease 
duration. 
Pieringer[323]  30 women with RA 
and 30 healthy 
controls 
Cross-sectional PWV increased in 
women with RA 
Angel[275] 35 patients RAand 
other rheumatic 
disorders 
commencing 
treament with TNF-
α inhibitors. 
Cross-sectional and 
longitudinal 
PWV reduced by 
treatment 
Holmes [256] 59 patients with RA Cross-sectional PWV increased in 
patients with RA but 
not correlated to 
CRP levels 
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Table 3 showing study cohorts studied in each paper. 
 
 
 
∞Only subjects aged from 30 to 70 years were included in this paper, as per protocol. 
 
 
 EURIDISS 
1992 
EURIDISS 
1997 
EURIDISS 
2002 
EURIDISS 
2007 
0RAR  
2007 
Community 
controls 
2009 
Paper 1 x x x    
Paper 2    x ∞ x∞ x∞ 
Paper 3 x   x   
Paper 4  x  x    
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10. Erratum 
In paper 2 there is regrettably an error in table 2. The estimated marginal mean of lnNT-
proBNP in patients with active RA is 2.40 and not 2.09, the standard deviations and p values 
for the differences are correct. 
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Abstract
Introduction Disease activity in patients with rheumatoid
arthritis (RA) is associated with increased cardiovascular
morbidity and mortality, of which N-terminal pro-brain natriuretic
peptide (NT-proBNP) is a predictor. Our objective was to
examine the cross-sectional and longitudinal associations
between markers of inflammation, measures of RA disease
activity, medication used in the treatment of RA, and NT-proBNP
levels (dependent variable).
Methods Two hundred thirty-eight patients with RA of less than
4 years in duration were followed longitudinally with three
comprehensive assessments of clinical and radiographic data
over a 10-year period. Serum samples were frozen and later
batch-analyzed for NT-proBNP levels and other biomarkers.
Bivariate, multivariate, and repeated analyses were performed.
Results C-reactive protein (CRP) levels at baseline were cross-
sectionally associated with NT-proBNP levels after adjustment
for age and gender (r2 adjusted = 0.23; P < 0.05). At the 10-
year follow-up, risk factors for cardiovascular disease were
recorded. Duration of RA and CRP levels were independently
associated with NT-proBNP in the final model that was adjusted
for gender, age, and creatinine levels (r2 adjusted = 0.38; P <
0.001). In the longitudinal analyses, which adjusted for age,
gender, and time of follow-up, we found that repeated measures
of CRP predicted NT-proBNP levels (P < 0.001).
Conclusion CRP levels are linearly associated with levels of NT-
proBNP in cross-sectional and longitudinal analyses of patients
with RA. The independent associations of NT-proBNP levels
and markers of disease activity with clinical cardiovascular
endpoints need to be further investigated.
Introduction
Patients with rheumatoid arthritis (RA) have a two- to three-
fold increase in cardiovascular mortality and morbidity [1,2].
Several studies have reported an association between dis-
ease activity and cardiovascular mortality [3-5]. Population-
based studies have also shown an increased prevalence of
congestive heart failure (CHF) in patients with RA compared
with healthy controls and patients with osteoarthritis [6,7].
Measures of disease activity and severity such as C-reactive
protein (CRP), disability index, pain, and global severity are
associated with an increased odds ratio for both concurrent
and subsequent CHF [6,8].
The level of N-terminal pro-brain natriuretic peptide (NT-
proBNP) predicts cardiac mortality and morbidity in the gen-
eral population as well as in cohorts of patients with heart fail-
ure and stable coronary heart disease [9-12]. NT-proBNP, the
biologically inactive N-terminal fragment of the active hormone
BNP, has a longer half-life than the active hormone and is a via-
ble biomarker of cardiovascular disease (CVD) [13]. In the
healthy heart, the main site of BNP production is in the atrial
cardiomyocytes, but as the heart fails fetal gene programs are
AIMS1 = Arthritis Impact Measurement Scales 1; anti-CCP = anti-cyclic citrullinated peptide antibody; BMI = body mass index; BNP = brain natriu-
retic peptide; CHF = congestive heart failure; CI = confidence interval; COX-2 = cyclooxygenase-2; CRP = C-reactive protein; CVD = cardiovascular 
disease; DAS28 = disease activity score of 28 joints; DMARD = disease-modifying anti-rheumatic drug; ELISA = enzyme-linked immunosorbent 
assay; HAQ = Stanford Health Assessment Questionnaire; NSAID = non-steroidal anti-inflammatory drug; NT-proBNP = N-terminal pro-brain natriu-
retic peptide; RA = rheumatoid arthritis; RF = rheumatoid factor; SD = standard deviation; Sharp score = van der Heijde modified Sharp criteria; TNF 
= tumor necrosis factor.
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activated and the ventricular myocardium becomes the main
site of BNP production, releasing the peptide in response to
stretch or ischemia [9,14].
The associations between clinical and laboratory markers of
RA disease activity and levels of NT-proBNP have not been
examined. There is also a lack of knowledge on the relationship
between exposure to drugs used in the treatment of RA (glu-
cocorticoids, disease-modifying anti-rheumatic drugs
[DMARDs], non-steroidal anti-inflammatory drugs [NSAIDs],
and cyclooxygenase-2 [COX-2] inhibitors) and NT-proBNP
levels in patients with RA. Our objective, therefore, was to
examine the cross-sectional and longitudinal associations
between markers of inflammation, RA disease activity, medica-
tion used, and NT-proBNP levels (dependent variable).
Materials and methods
Patients
We followed 238 patients with RA of less than 4 years in dura-
tion longitudinally with comprehensive assessments of clinical
and radiographic data at baseline and after 5 and 10 years
[15]. The patients had all been recruited to the EUropean
Research on Incapacitating DIsease and Social Support
(EURIDISS) project, which was initially established in 1991.
The project has been approved by the Norwegian Regional
Committee for Research Ethics. All patients have signed an
informed consent form on inclusion and at each follow-up
assessment. At baseline, mean (range) age was 51.6 years
(23 to 70), mean (standard deviation, SD) disease duration
was 2.3 years (1.2), and 73.5% were female. Serum samples
were collected from 237 patients at baseline, 126 patients
after 5 years, and 145 after 10 years. Eighty-nine patients
were lost to follow-up at the 10-year visit (42 declined to par-
ticipate, 5 had moved out of the area, 35 had died, and 7 gave
other reasons not to participate).
Measures of disease activity
Disease activity was measured by joint tenderness, which was
assessed at all examinations, and the Ritchie score was calcu-
lated [16]. Swollen joint counts were included at the 5- and
10-year assessments; that is, the disease activity score of 28
joints (DAS28) was not available from the baseline visit [17].
Surrogate measures of cumulative disease activity were health
status and joint destruction. Health status was measured by
the self-administered Stanford Health Assessment Question-
naire (HAQ) and the Arthritis Impact Measurement Scales 1
(AIMS1) [18,19]. Joint destruction was measured by radio-
graphic damage of the hands and scored according to the van
der Heijde modified Sharp criteria (referred to below as the
Sharp score) [20]. Comorbidities were recorded by a trained
study nurse at the 5- and 10-year follow-ups using a checklist
modified from AIMS1 concerning the presence of 16 possible
comorbidities. One of these items addresses the presence of
angina, myocardial infarction, or other cardiac diseases. At the
10-year follow-up, known risk factors of CVD (hypertension,
cholesterol, smoking, and creatinine) were also recorded. The
use of NSAIDs, DMARDs, and glucocorticoids was recorded
by the study nurse at all assessments (the use of COX-2 inhib-
itors was recorded only at the 10-year follow-up).
Biomarkers
NT-proBNP was measured using a Modular E 170 device
(Roche Diagnostics, Mannheim, Germany). The erythrocyte
sedimentation rate was analyzed by the Westergren method at
the time of examination, whereas the other biological markers
were analyzed from frozen serum or plasma anti-cyclic citrulli-
nated peptide antibody (anti-CCP) by enzyme-linked immuno-
sorbent assay (ELISA) (Inova Diagnostics, San Diego, CA,
USA) and CRP by phyCardioPhase high-sensitivity CRP
nefelometri (Dade Behring, now part of Siemens AG, Munich,
Germany). Rheumatoid factor (RF) IgM was analyzed using
the ELISA method [21].
Statistical analyses
NT-proBNP levels were dichotomized according to the
national gender- and age-adjusted reference levels modified
from Roche Diagnostics guidelines [22] (female: < 50 years of
age, NT-proBNP  20 pmol/L; 50 to 70 years of age,  30
pmol/L; > 70 to 80 years of age,  100 pmol/L, and > 80 years
of age,  200 pmol/L; male: < 50 years of age, NT-proBNP 
10 pmol/L; 50 to 70 years of age,  20 pmol/L; > 70 to 80
years of age,  60 pmol/L, and > 80 years of age,  100 pmol/
L). Groups were compared using the 2 and Mann-Whitney U
tests as appropriate.
In the regression analyses, NT-proBNP was entered as a con-
tinuous dependent variable and was log-transformed to obtain
normality. The presented -coefficients have been trans-
formed from the log value. All other variables were entered
untransformed, and all analyses were adjusted for age and
gender. The baseline cross-sectional associations between
demographic, disease activity, and severity variables (gender,
age, CRP, Sharp score of hands, Ritchie score, HAQ disease
duration, RF IgM, anti-CCP, and use of DMARDs, steroids, or
NSAIDs) and NT-proBNP levels were explored in bivariate lin-
ear regression analyses. Variables that were associated (P <
0.10) with NT-proBNP were then entered into a multivariate
linear regression model and subsequently removed in a step-
wise manner according to levels of significance. These ana-
lytic procedures were also applied to the cross-sectional data
from the 10-year follow-up examination, which gave the oppor-
tunity of controlling not only for cardiovascular risk factors,
including body mass index (BMI) and creatinine levels, but also
for the presence of self-reported CVD.
Mixed model linear regression was used to examine longitudi-
nal associations [23]. This is a longitudinal linear regression
analysis that controls for multiple testing of the same patient
by modelling the covariance between the repeated measure-
ments of each individual as a clustered random effect. An
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unstructured covariance matrix was used in our analysis
assuming that the correlation for each level of within-subject
factors is different. The intra-subject variance is then used to
calculate the standard error of the regression coefficient. The
mixed model procedure deals with missing values by assum-
ing them to be missing at random without removing the individ-
ual from the dataset. We investigated the change in NT-
proBNP levels over time and examined associations between
measures of inflammation, RA disease activity, medication
taken, known CVD risk factors, and NT-proBNP (dependent
variable). All analyses were performed using SPSS version 14
(SPSS Inc., Chicago, IL, USA). P values of less than 0.05 were
considered significant.
Results
At baseline, 35 patients had pathological levels of NT-proBNP.
Disease characteristics were similar between these sub-
groups (normal versus elevated NT-proBNP), although the
group with elevated NT-proBNP levels had significantly higher
CRP levels (Table 1). CRP levels at baseline were significantly
associated with NT-proBNP in the linear regression analyses
(Table 2). This significant association was also maintained in
the multivariate linear regression analyses, which included the
interaction between age and gender as an effect modifier. The
use of DMARDs, NSAIDs, or glucocorticoids was not signifi-
cantly associated with NT-proBNP levels. The analysis was
repeated with glucocorticoid use dichotomized according to a
dosage greater than or less than 7.5 mg (P = 0.189).
At the 10-year follow-up examination, age, gender, BMI, creat-
inine, CRP, and disease duration were significantly associated
with NT-proBNP levels (Table 3). Consistent with our baseline
analyses, CRP and NT-proBNP levels remained significantly
associated in the multivariate analysis. The significant associ-
ation between disease duration and NT-proBNP levels was
also maintained. The model was also valid if self-reported CVD
was entered as a covariate ( coefficient for CVD 1.65, 95%
confidence interval [CI] 1.15 to 2.37; P = 0.007). The pres-
ence of hypertension, smoking status, and prevalent use of
glucocorticoids, DMARDs (including subgroups of tumor
necrosis factor [TNF] inhibitors and methotrexate users),
COX-2 inhibitors, or NSAIDs was not significantly associated
with NT-proBNP levels (data not shown).
In the repeated mixed model analysis, several markers of dis-
ease activity were associated with NT-proBNP levels, but after
multivariate adjustment for time of follow-up, only CRP
remained a significant predictor in the final model (Table 4).
NT-proBNP levels increased between each follow-up visit and
the interactions between age and gender and gender and time
of follow-up were significant effect modifiers. The model
remained significant if self-reported CVD at the 10-year follow-
up was entered as a covariate ( coefficient for CVD 1.48,
95% CI 1.11 to 1.98; P = 0.008).
Discussion
NT-proBNP has been shown to be an independent predictor
of cardiovascular morbidity and mortality [9-11], and disease
activity in RA correlates with mortality, CVD, and CHF [5,6].
Hence, it is of interest to investigate how markers of inflamma-
tion and disease activity are related to NT-proBNP in a longi-
tudinal perspective. We found significant cross-sectional and
longitudinal associations between CRP and levels of NT-
proBNP in this cohort of RA patients with less than 4 years of
disease duration at inclusion. CRP remained an independent
predictor of NT-proBNP levels after controlling for known car-
diovascular risk factors and the presence of self-reported CVD
at the 10-year follow-up and in the longitudinal analyses.
Table 1
Baseline characteristics with comparison between patients with pathological versus normal levels of NT-proBNP
All patients NT-proBNP-negativea n = 202 NT-proBNP-positivea n = 35 P value
Age, years 51.9 (13.0) 51.4 (12.9) 54.3 (13.7) 0.17
Female gender 175 (73.5) 151 (74.8) 23 (65.7) 0.26
Disease duration, years 2.3 (1.2) 2.2 (1.1) 2.4 (1.3) 0.41
RF IgM-positive,  25 114 (47.9) 97 (48.0) 16 (45.7) 0.80
Anti-CCP-positive,  25 144 (60.5) 125 (61.9) 18 (51.4) 0.24
Sharp score 6.8 (11.8) 6.8 (12.3) 6.5 (8.1) 0.20
C-reactive protein, mg/L 9.9 (12.7) 9.2 (11.8) 13.9 (15.8) 0.05
DMARD user 124 (52.1) 104 (51.5) 19 (54.3) 0.76
NSAID user 109 (45.8 92 (45.5) 17 (48.6) 0.74
Glucocorticoid user, oral 65 (27.2) 51 (25.2) 14 (40) 0.07
Values are presented as mean (standard deviation) for continuous variables and as number (percentage) for counts. aAge- and gender-adjusted reference levels. anti-
CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal 
pro-brain natriuretic peptide; RF, rheumatoid factor; Sharp score, van der Heijde modified Sharp criteria.
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Our findings are intriguing as the relationship between BNP/
NT-proBNP values and the risk of CVD may not be dependent
on a threshold value of BNP/NT-proBNP but rather represents
a continuum [11,24]. Wang and colleagues [11] found that a
single measurement of BNP provided prognostic information
in an unselected population of 3,346 persons without heart
failure followed for a mean of 5.2 years. An increase of BNP
levels by 1 SD was associated with a 77% increased risk of
developing heart failure and a 28% increased risk of a first car-
diovascular event [11]. BNP has been validated as a marker of
CVD in patients with RA. Harney and colleagues [25] found
that BNP levels were significantly higher in 26 patients with
RA than in controls and correlated with end diastolic volume
(r2 = 0.83), end systolic volume (r2 = 0.62), and left ventricular
mass (r2 = 0.4). Levels of NT-proBNP have been found to cor-
relate closely with BNP (r = 0.9; P < 0.001) [24].
Increased levels of inflammatory markers are associated with
an increased risk of cardiovascular morbidity and mortality
[26,27]. We found that CRP was significantly associated with
levels of NT-proBNP at all time points. Flares in inflammatory
activity might be better predictors of cardiovascular events
than long-term exposure to low-grade inflammation. Indeed,
there is evidence that the initiation of CHF in RA patients is
preceded by a flare in disease activity [8]. Radiographic pro-
gression and the HAQ score are surrogate measures of cumu-
lative disease activity, although we acknowledge that there are
wide inter-individual variations [28-31]. We found no signifi-
cant association between these measures and NT-proBNP
levels in our multivariate longitudinal analyses. Previous
reports on the association between joint destruction and CVD
in RA have been inconsistent; Wållberg-Jonsson and col-
leagues [5] demonstrated that early progression of erosions
increased the risk of cardiovascular events. Solomon and col-
leagues [1], on the other hand, did not find that joint erosions
were significantly associated with cardiovascular death or
myocardial infarction in multivariate analyses. However, we did
find disease duration to be significantly associated with NT-
proBNP levels at the 10-year cross-sectional analysis. As all
patients had a disease duration of 4 years or less at inclusion,
the correlation with NT-proBNP levels after 10 years is difficult
to interpret. A link between RA disease duration and increased
CVD risk can be questioned. In the Rochester cohort, no asso-
ciation was found between risk of heart failure or cardiovascu-
lar death and RA disease duration [7,32], nor did Book and
colleagues [33] find an association between disease duration
and mortality.
To our knowledge, no previous study has examined the asso-
ciation between markers of inflammation in RA and BNP/NT-
proBNP. It could be argued that the association between CRP
and NT-proBNP identified in our study is a consequence of the
inflammatory nature of ventricular remodelling. Patients with
RA are not only exposed to systemic inflammation from their 
Table 2
Cross-sectional associations at baseline between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity
Adjusted linear regression Multivariate linear regression
 coefficient P value  coefficient P value
Age 1.02 (1.01–1.03) < 0.001 1.009 (1.00–1.02) 0.04
Male gender 0.74 (0.59–0.95) 0.02 0.10 (0.04–0.23) < 0.001
C-reactive proteina 1.01 (1.01–1.02) 0.002 1.01 (1.01–1.02) 0.001
RF IgM-positivea, b 0.96 (0.79–1.17) 0.67
Anti-CCP-positivea, b 0.90 (0.74–1.10) 0.30
Gluocorticoid usera, b 1.17 (0.94–1.48) 0.16
DMARD usera, b 1.04 (0.85–1.26) 0.71
NSAID usera, b 0.97 (0.80–1.19) 0.81
Ritchie scorea 1.01 (0.99–1.03) 0.21
HAQa 1.06 (0.90–1.24) 0.47
Sharp scorea 1.00 (0.99–1.02) 0.93
Disease durationa 0.99 (0.91–1.08) 0.82
Age × male gender 1.04 (1.02–1.05) < 0.001
R2 adjusted 0.23 < 0.05
aAge- and gender-adjusted; bdichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; HAQ, 
Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; 
Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.
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Table 3
Cross-sectional associations at the 10-year follow-up between NT-proBNP (dependent variable) and rheumatoid arthritis disease 
activity, controlling for cardiovascular risk factors
Adjusted linear regression Multivariate linear regression
 coefficients P value  coefficients P value
Age 1.04 (1.03–1.05) < 0.001 1.04 (1.03–1.05) < 0.001
Male gender 0.92 (0.64–1.31) 0.64 0.76 (0.53–1.04) 0.09
Body mass indexa 0.96 (0.93–0.98) 0.001
Atherogenic indexa 0.95 (0.86–1.04) 0.25
Creatininea 1.02 (1.01–1.02) 0.001 1.01 (1.00–1.02) 0.04
C-reactive proteina 1.01 (1.0–1.03) 0.06 1.02 (1.00–1.02) 0.03
RF IgM-positivea, b 0.92 (0.72–1.19) 0.53
Anti-CCP-positivea, b 1.14 (0.88–1.45) 0.33
Ritchie scorea 1.00 (0.99–1.01) 0.87
DAS28a 1.05 (0.96–1.16) 0.27
HAQa 1.15 (0.94–1.41) 0.17
Sharp scorea 1.002 (1.00–1.01) 0.17
Disease durationa 1.14 (1.02–1.27) 0.02 1.15 (1.03–1.27) 0.01
R2 adjusted 0.38 < 0.001
aAge- and gender-adjusted; bdichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score of 28 joints; HAQ, Stanford 
Health Assessment Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van 
der Heijde modified Sharp criteria.
Table 4
Mixed model repeated measure linear regression showing the association between NT-proBNP (dependent variable) and markers 
of disease activity and treatment
Adjusted linear regression (CI) Multivariate linear regression (CI)
 coefficients (CI) P value  coefficients (CI) P value
Age 1.03 (1.02–1.03) < 0.001 1.02 (1.01–1.02) < 0.001
Male gender 0.81 (0.64–1.01) 0.06 0.12 (0.05–0.26) < 0.001
C-reactive proteina 1.01 (1.01–1.02) < 0.001 1.01 (1.01–1.02) < 0.001
HAQa 1.12 (1.00–1.27) 0.06
Prednisolonea, b 1.20 (1.03–1.41) 0.02
NSAIDa, b 0.90 (0.79–1.04) 0.14
DMARDa, b 0.95 (0.83–1.09) 0.49
Sharp scorea 1.01 (1.00–1.01) 0.001
Ritchie scorea 1.01 (1.00–1.02) 0.01
Time 1.04 (1.03–1.06) < 0.001 1.03 (1.02–1.05) < 0.001
Time × male gender 1.04 (1.01–1.07) 0.01
Age × male gender 1.03 (1.02–1.05) 0.01
aAge- and gender-adjusted; bdichotomized variable. CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment 
Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; Ritchie score, Ritchie articular index; Sharp score, 
van der Heijde modified Sharp criteria.
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arthritic disease, the failing heart itself may be invaded by
peripheral blood mononuclear cells that participate in left ven-
tricular remodelling. These and other inflammatory cells
release TNF- and interleukin-6, thereby increasing CRP lev-
els through upregulation of hepatic synthesis [27].
The strength of the present study is the prospective longitudi-
nal design with regular clinical examinations, blood sampling
with subsequent batch analyses, and documentation of radio-
graphic progression. NT-proBNP has been shown to tolerate
routine laboratory handling and may be analyzed from frozen
sera [10,34]. The validity of our model is supported by the
association between NT-proBNP levels and self-reported
CVD. Furthermore, in agreement with previous studies, creat-
inine levels predict NT-proBNP in the final model. NT-proBNP
is metabolized in the renal proximal tubule, and reduced renal
function partially accounts for the age-related increase in NT-
proBNP levels in the general population [14,35]. We found
BMI to be inversely correlated with NT-proBNP levels in the
adjusted bivariate analyses although it did not reach signifi-
cance in the multivariate analysis. Other studies have con-
firmed the inverse relationship between BMI and NT-proBNP
levels [36].
This study has several shortcomings. Two hundred thirty-eight
patients were included at baseline, and 145 completed the
10-year follow-up. The small scale of this study is a limitation
in the analyses. CVD in RA was not a major focus when the
cohort was established, and information relating to cardiovas-
cular comorbidity, smoking, concomitant medication, blood
pressure, or BMI was not recorded at baseline. The presence
of CVD was recorded by a questionnaire at the 10-year follow-
up and we did not have the opportunity to verify the diagnosis
by searching the medical records. Cause of death for the 35
patients who died during the study was not recorded. Thus,
we considered that the data were not sufficiently robust to
allow an explorative analysis of how levels of NT-proBNP pre-
dict future CVD. However, the patients were requested to
report current medication. There was perfect agreement
between self-reported CVD and the reported prescription of
medication typically used to treat CVD, such as anti-hyperten-
sive drugs, anti-platelet agents, or nitrates, allowing for an
internal consistency check.
Conclusion
CRP levels were linearly associated with levels of NT-proBNP
in this cross-sectional and longitudinal study of 238 patients
with RA. Further studies are needed to elucidate how this
biomarker can be implemented in clinical decision making in
RA.
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 ABSTRACT 
 Objectives  To compare markers of cardiovascular 
disease (CVD) risk between patients with rheumatoid 
arthritis (RA) in an active disease state and those with 
RA in remission, and to compare both groups with 
community controls. 
 Methods  113 patients with RA and 86 community 
controls were assessed across a panel of biomarkers 
for CVD. RA in remission was deﬁ ned as Clinical Disease 
Activity Index 2.8. Community controls were selected 
at random by Statistics Norway, and controls were 
matched with patients in the cohorts in strata using 
details of age, sex and residential area. A panel of 
biomarkers (N-terminal pro-brain natriuretic peptide 
(NT-proBNP), total cholesterol, reactive hyperaemia index 
(RHI), pressure measurements, measures of arterial 
stiffness and intima-media thickness) were compared 
between patients with active RA and those with RA in 
remission. Both groups were compared with controls. 
In addition, biomarker levels were compared across 
subgroups based on anticyclic citrullinated peptide status, 
level of joint destruction and presence of extra-articular 
manifestations. 
 Results  Patients with active RA had signiﬁ cantly 
higher levels of NT-proBNP, brachial systolic pressure, 
augmentation index and central systolic pressure but 
lower cholesterol than patients in remission and controls. 
In addition, patients with active RA had signiﬁ cantly 
higher levels of pulse wave velocity and worse RHI than 
patients in remission. Comparison across other subgroups 
gave less consistent differentiations in levels of CVD risk 
markers. 
 Conclusion  Patients with active RA, but not those 
in remission, had signiﬁ cantly increased levels of CVD 
risk markers. These results link inﬂ ammatory activity 
to markers of CVD risk in patients with RA and may 
indirectly support the notion that remission in RA confers 
diminished cardiovascular morbidity. 
 BACKGROUND 
 Patients with rheumatoid arthritis (RA) have an 
increased risk of cardiovascular disease (CVD) and a 
reduced life expectancy.  1    2  The increased occurrence 
of CVD is partly explained by an adverse combina-
tion of traditional risk factors and factors related to 
RA disease activity such as inﬂ ammation. 
 The individual risk of CVD can be assessed by 
biomarkers that reﬂ ect many facets of CVD-related 
pathology and morbidity.  3  The pathogenesis of 
CVD involves endothelial dysfunction, arterial 
stiffening and atherosclerosis which may ultimately 
lead to clinical disease, evident as hypertension, 
myocardial infarction, stroke or heart failure.  4    5  
A huge array of biomarkers is becoming available 
to audit the CVD risk at the level of the individual. 
 The primary aim of the current analyses was 
to compare levels of CVD risk markers between 
patients with clinically active RA and those with 
RA in remission and to compare these two groups 
with community controls. We also compared CVD 
risk markers between subgroups of RA patients 
categorised according to anticyclic citrullinated 
peptide (anti-CCP) status, level of joint destruction 
and presence of extra-articular manifestations. 
 METHODS 
 One hundred and thirteen patients with RA and 
86 community controls aged 30–70 years were 
assessed across a panel of biomarkers for CVD. 
The data for the patients with RA were derived 
from the 15-year follow-up of the EURIDISS 
cohort (n=80)  6  and the 10-year follow-up of the 
Oslo RA register (n=33).  7  The patients had been 
diagnosed according to the 1987 American College 
of Rheumatology criteria.  8  The patients were strat-
iﬁ ed according to the following groups: female 
versus male, age in decades and residential area. 
Two hundred community controls were randomly 
selected by Statistics Norway from the inhabitants 
of Oslo to match these stratiﬁ cations. The only 
exclusion criterion was a history of inﬂ ammatory 
arthritis. Demographic and health status variables 
were collected by a self-reported questionnaire, 
but the subjects could request help from attend-
ing staff. Body mass index (BMI) was calculated. 
The patients were requested to abstain from food, 
drink (except for water) and smoking for at least 
3 h prior to examination. 
 RA disease activity 
 A trained study nurse blinded to the CVD risk pro-
ﬁ le of the patients assessed the number of swol-
len and tender joints (28 joint counts), and disease 
activity was assessed by the Clinical Disease 
Activity Index (CDAI) as the sum of the number of 
swollen joints + number of tender joints + patient 
global VAS (in cm) + investigator global VAS (in 
cm).  9  Patients with a CDAI ≤2.8 were considered 
to be in remission.  10  Joint destruction was mea-
sured by radiographic damage of the hands and 
scored according to the van der Heijde-modiﬁ ed 
Sharp criteria (vdHSS).  11  The presence of extra-
articular manifestations was self-reported using a 
modiﬁ cation of the AIMS 2 questionnaire.  12  
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thickness (IMT) of a 5 mm long section of the far wall, 10 mm 
proximal to the carotid bulb, was obtained by the AMS analy-
sis software (Artery Measurement System, Tomas Gustavsson, 
Gothenburg, Sweden). Each 5 mm section generated approxi-
mately 50 IMT calculations and median values were used when 
comparing study groups. 
 The reliability of all biomarkers was tested by repeated exam-
inations in a subset of patients. The inter-reader correlation 
coefﬁ cient was then calculated. For all CVD risk markers the 
inter-reader correlation coefﬁ cient was found to be good (see 
online supplement for further information). 
 The Framingham 10-year risk of coronary heart disease 
and the European Society of Cardiology SCORE 10-year risk 
of CVD-related death were calculated using standardised risk 
 calculators.  17    18  
 Statistical analyses 
 Bivariate comparisons were made using the Student t test, χ² test 
or Mann–Whitney U test as appropriate. 
 The level of CVD risk markers was compared across the fol-
lowing groups using analysis of covariance (ANCOVA): active 
RA, RA in remission versus community controls; anti-CCP sta-
tus positive versus negative; vdsHss joint destruction ≤ median 
versus > median; and presence versus absence of extra- articular 
manifestations. All analyses were adjusted for age and sex. 
Skewed variables were log transformed. The validity of the 
ANCOVA models was explored by examining the following vari-
ables as possible confounders in the ﬁ nal model: smoking (now/
never), BMI, education, presence of relevant comorbidities (prior 
myocardial infarction, cerebral insult and diabetes) and current 
use of CVD-related medication (statins and anti hypertensive 
medication). In addition, the heart rate was explored as a pos-
sible confounder of brachial and central systolic pressure and 
PWV, and height as a confounder of AIx. Disease duration and 
current RA disease treatments (methotrexate, prednisolone, 
tumour necrosis factor α (TNFα) inhibitor) were entered into 
the models which compared patients across categories of RA 
disease activity. The results were further veriﬁ ed by construct-
ing a case-control cohort matching a patient with active RA to a 
patient in remission of the same age and sex. In a mixed model 
procedure we compared levels of CVD risk markers between 
these groups. A variable denoting each pair was included in the 
model as a random effect. 
 A logistic regression model was constructed with active RA 
versus RA in remission as the dependent variable in order to 
assess the independent contribution of each CVD risk marker. 
Individual CVD risk markers were entered consecutively into 
models that were adjusted for age and sex. CRP was omitted 
from these analyses at it is a marker of both RA disease activ-
ity and CVD risk. Variables that were signiﬁ cant at p≤0.10 were 
entered into the multivariate model and removed according to 
level of signiﬁ cance. Due to multicollinearity, separate models 
were constructed, each of which only included one of the follow-
ing variables— brachial systolic pressure, central systolic pressure 
and AIx—and the model with the greatest Nagelkerke value and 
accuracy was chosen. Rejected variables were re- entered into the 
ﬁ nal model to check for possible confounding. 
 The statistical analyses were performed using SPSS 
Version 14. 
 RESULTS 
 Eighty-two patients had active RA (CDAI >2.8) and 31 were 
in remission (CDAI ≤2.8). The demographic data are presented 
 Soluble biomarkers 
 Biomarkers were examined consecutively: erythrocyte sedi-
mentation rate by the Westergren method, C reactive protein 
(CRP) and total cholesterol by COBAS 6000 (Roche Diagnostics, 
Basel, Switzerland), N-terminal pro-brain natriuretic peptide 
(NT-proBNP) by a Modular E170 device (Roche Diagnostics, 
Basel Switzerland; coefﬁ cient of variation (CV) 7.6–9.7%) and 
anti-CCP using an ELISA method (Inova Diagnostics, San Diego, 
California, USA). 
 Markers of CVD risk 
 Brachial blood pressure was measured after a 5 min rest in a 
supine position using the OMRON M7 (Kyoto, Japan). Several 
measurements were made until two measurements differed by 
≤5 mm Hg in both systolic and diastolic mm Hg as well as heart 
rate, and averages were then calculated. We performed pulse 
wave analysis assessments using the Sphygmocor apparatus 
(Atcor, West Ryde, Australia). The apparatus uses applanation 
tonometry, equalising the circumferential pressure by slightly 
ﬂ attening the artery to obtain accurate pressure waveforms. 
Patients suffering from atrial ﬁ brillations were excluded from 
the analysis. Several recordings were made in each patient and 
the recordings considered to have the highest quality accord-
ing to predetermined requirements were selected for further 
analyses.  13  
 The reactive hyperaemia index (RHI), also called the digital 
hyperaemic response, was measured using the Itamar appara-
tus (Caesarea, Israel).  14  Eighteen controls did not participate in 
this examination for logistical reasons. The patients were asked 
to recline on a bed in a comfortable position and probes were 
attached to bilateral index ﬁ ngers. A sphygmomanometer cuff 
was wrapped around the upper arm. After a 5 min recording 
of the digital pulse, the cuff was inﬂ ated to 200 mm Hg and 
the recording examined for any sign of pulsatile activity on 
the occluded side, in which case the cuff was further inﬂ ated, 
although not above 300 mm Hg. After a 5 min occlusion the cuff 
was released and a further 5 min of recording was made during 
which the hyperaemic phase occurred. The RHI was calculated 
by the software installed on the Itamar. 
 Pulse wave velocity (PWV) was calculated from knowing 
both the transit time for the pulse wave travelling from the 
heart to two sites and the distance between these sites.  15  We 
chose to estimate the carotid-femoral PWV between the site on 
the carotid and on the femoral artery where the pulse was most 
strongly palpated. The recordings of the foot of the pressure 
wave at the carotid and femoral artery were gated to an ECG as 
a measure of transit time. The distance between the suprasternal 
notch and the measurement site on the carotid artery was sub-
tracted from the distance between the suprasternal notch and 
the site on the femoral artery. 
 Central systolic pressure and the augmentation index (AIx) 
were derived by applying a validated transfer system to record-
ings of the arterial pressure waves at the radial artery. Central 
systolic pressure is an estimation of the systolic pressure in the 
ascending aorta. AIx is deﬁ ned as the change in pressure between 
the second and ﬁ rst systolic peaks as a percentage of the pulse 
pressure and was standardised to a heart rate of 75 bpm.  16  
 B-mode ultrasonographic examinations were performed 
on bilateral common carotid arteries using a GE Vivid 7 ultra-
sound scanner (GE Vingmed Ultrasound, Horten, Norway) with 
a 12 Mhz probelinear matrix array transducer.   9–14  The images 
were analysed ofﬂ ine from JPG images as single readings per-
formed by two of the authors (ES and JH). The intima-media 
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in the controls ( table 2 ). We did not identify any variable that 
altered the consistency of our ﬁ ndings by confounding several 
models. 
 Thirty pairs were matched in the case–control study. The 
comparisons conﬁ rmed the results of lower total cholesterol 
(p=0.02), worse RHI (p=0.001), higher CRP (p=0.02), PWV 
(p=0.01) and AIx (p=0.01) in patients with active RA compared 
with patients in remission. 
 The logistic regression analyses with active RA versus RA in 
remission as the dependent variable found that a model com-
posed of the following variables best differentiated between 
these patients: RHI (OR 0.15 (95% CI 0.06 to 0.39)), AIx (OR 
1.10 (95% CI 1.02 to 1.18)) and PWV (OR 1.72 (95% CI 1.10 
to 2.68)), with adjustments for age (OR 0.09 (95% CI 0.84 to 
0.98)) and sex (female sex OR 2.98 (95% CI 0.66 to 13.50)). The 
accuracy of the ﬁ nal model was 84%, sensitivity 96%, while the 
Nagelkerke value (pseudo R²)  19  was 0.42. Entering use of antihy-
pertensive medication into the model (OR 11.46 (95% CI 1.76 
in  table 1 and show some differences between the groups, 
 especially for active RA versus the controls. The participation 
rate of the community controls was 43%, while 57% of the 
surviving participants of the EURIDISS and Oslo RA register 
cohorts agreed to participate at the 15- and 10-year follow-up, 
respectively. 
 The results of the adjusted comparisons of CVD risk mark-
ers (estimated marginal means) are shown in  table 2 . Compared 
with patients in remission, those with active disease had higher 
CRP, NT-proBNP, PWV, brachial systolic pressure, AIx and cen-
tral systolic pressure, whereas total cholesterol and RHI were 
lower in patients with active RA (p<0.05 for all comparisons). 
The CVD risk proﬁ le in patients with active RA remained signif-
icantly disadvantageous when compared with community con-
trols, although the total cholesterol was lowest in the patients 
with RA. In contrast, patients in remission only had signiﬁ cantly 
higher CRP levels when compared with the controls, and PWV 
and RHI levels were more favourable in these 31 patients than 
 Table 1  Cross-sectional demographic data compared across groups 
 Variable 
 Active RA 
(n=82) 
 RA in remission 
(n=31) 
 Population 
controls (n=86) 
 p Value 
(active vs remission) 
 p Value 
(active vs control) 
 p Value 
(remission vs control) 
Demographic data
 Age 56.9 58.1 (8.0) 53.7 (10.5) 0.54 0.05 0.02
 Female sex 64 (78.0) 22 (71.0) 53 (61.6) 0.43 0.02 0.35
 Education 35 (42.7) 14 (45.2) 38 (46.3) 0.81 0.64 0.91
 Smoking 21 (25.9) 4 (12.9) 20 (23.3) 0.14 0.69 0.22
 BMI 26.3 (5.6) 25.0 (3.9) 25.4 (4.0) 0.28 0.22 0.66
 Disease duration 17.1 (2.1) 16.9 (1.7)  0.70   
Presence of comorbidities
 MI 4 (5.5) 0 (0.0) 3 (3.7) 0.19 0.60 0.29
 Stroke 6 (7.3) 1 (3.2) 1 (1.2) 0.42 0.05 0.45
 Diabetes 9 (11.0) 1 (3.2) 2 (2.4) 0.20 0.03 0.79
Current use of medication
 Antihypertensives 31 (37.8) 3 (9.7) 18 (21.2) 0.004 0.02 0.16
 Statins 16 (19.5) 2 (6.5) 13 (15.3) 0.09 0.47 0.21
 Prednisolone 27 (32.9) 4 (12.9)  0.03   
 Methotrexate 28 (34.1) 9 (29.0)  0.61   
 TNFα inhibitors 24 (30.0) 5 (16.1)  0.14   
 Crude mean (SD) values presented and numbers (percentages) for counts. 
 BMI, body mass index; MI, myocardial infarction; RA, rheumatoid arthritis; smoking, smoking ever vs never; stroke, cerebrovascular accident due to ischaemia or haemorrhage; 
TNFα, tumour necrosis factor α. 
 Table 2  Cardiovascular risk markers compared across groups 
 Variable 
 Active RA 
(n=82) 
 RA in remission 
(n=31) 
 Population 
controls (n=86) 
 p Value 
(active vs remission) 
 p Value 
(active vs control) 
 p Value 
(remission vs control) 
Soluble biomarkers
 CRP (mg/l) 8.65 (1.49) 5.35 (2.30) 3.13 (1.39) 0.001 <0.000 0.09
 Total cholesterol (mmol/l) 5.22 (0.13) 5.77 (.20) 5.84 (0.12) 0.02 <0.000 0.77
 HDL cholesterol (mmol/l) 1.60 (0.06) 1.61 (0.09) 1.72 (0.06) 0.90 0.14 0.33
 Atherogenic index 3.58 (0.13) 3.81 (0.20) 3.67 (0.12) 0.23 0.17 0.24
 lnNT-proBNP (pmol/l) 2.09 (0.11) 1.99 (0.17) 2.09 (0.11) 0.04 0.04 0.61
Peripheral biomarkers
 RHI 2.02 (0.07) 2.60 (0.11) 2.13 (0.07) <0.000 0.29 <0.000
 Brachial systolic pressure (mm Hg) 134.47 (2.01) 126.47 (3.07) 127.34 (1.85) 0.03 0.01 0.81
Central biomarkers
 PWV (m/s) 8.09 (0.16) 7.31 (0.23) 7.84 (0.14) 0.003 0.21 0.05
 AIx 22.57 (1.05) 18.35 (1.53) 18.20 (0.95) 0.02 0.002 0.93
 Central systolic pressure (mm Hg) 124.64 (1.94) 116.20 (2.85) 117.33 (1.77) 0.01 0.005 0.74
 IMT (mm) 0.76 (0.02) 0.73 (0.03) 0.74 (0.02) 0.38 0.45 0.75
Composite risk score
 Framingham 10.93 (0.64) 10.11 (0.90) 10.15 (0.53) 0.44 0.34 0.97
 SCORE 3.38 (0.27) 2.46 (0.38) 2.88 (0.23) 0.04 0.15 0.34
 Estimated marginal mean (SE) presented with adjustments for age and sex. 
 AIx, augmentation index; BMI, body mass index; CRP, high sensitivity C reactive protein; Framingham, Framingham risk score; HDL cholesterol, high density lipoprotein; 
IMT, intima-median thickness; lnNT-proBNP, natural logarithm of N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RHI, reactive hyperaemia index; SCORE, European 
Society of Cardiology SCORE risk calculator. 
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signiﬁ cant differences in the Framingham score between patient 
groups and controls, although SCORE was higher in patients 
with active RA ( table 2 ). The use of SCORE may be advanta-
geous for our patients for two reasons: it can be calculated using 
the atherogenic index (dividing the total cholesterol by the high 
density lipoprotein) and it is based on European populations. 
Heterogeneous ﬁ ndings concerning the lipid proﬁ les of patients 
with RA have been reported. Adverse lipid proﬁ les have been 
found in cohorts across a range of disease durations and activity 
states.  26    27  However, RA and chronic inﬂ ammation have also 
been shown to correlate with reduced total cholesterol levels 
(high density, low density and very low density lipoproteins), 
possibly due to increased clearance of low density lipoprotein 
cholesterol by the reticuloendothelial system or decreased lipo-
protein lipase activity.  22    28 –31 
 The RHI is a measure of endothelial function which corre-
lates with the gold standard of coronary endothelial function 
measurements and was recently shown to predict cardiovascu-
lar events in a prospective study.  14    32  Flow-mediated dilation, 
the classic method of non-invasive endothelial function assess-
ment, has been found to be decreased in patients with RA.  33    34  
Endothelial dysfunction may impact on arterial stiffness through 
nitric oxide, which is important in arterial stiffness regulation.  35  
Inﬂ ammatory cytokines may also act through upregulation 
of angiotensin type 1 receptors to cause vasoconstriction and 
hypertension.  24    36  Furthermore, an injury to the endothelium 
can proceed to intimal thickening with a decrease in vascular 
wall contractile elements as smooth muscle cells migrate to the 
intima, multiply and lay down extracellular matrix.  37  The resul-
tant arterial stiffening is characterised by increased vascular col-
lagen formation, calciﬁ cation and breakdown of elastin.  15  
 Carotid-femoral PWV pulse wave velocity, AIx and central 
systolic pressures are measures of arterial stiffening and wave 
reﬂ ection that have been used to predict cardiovascular mor-
bidity and mortality in numerous studies.  15    38–41  The AIx and 
central pressure estimations quantify the pressure ampliﬁ cation 
to 74.80)) removed PWV from the model and gave an improve-
ment in the Nagelkerke value of 0.07, a slight decrease in the 
sensitivity of 1.3%, without altering the accuracy of the model. 
 Fifty-ﬁ ve patients were anti-CCP positive, the median vdHSS 
was 10 (range 0–152) and 13 patients (11.5%) had current or 
a history of extra-articular manifestations. The distribution of 
CVD risk markers was similar overall across these categories 
( table 3 ). 
 DISCUSSION 
 This study shows that patients in RA disease remission score 
signiﬁ cantly better than patients with active RA across a range 
of biomarkers predicting CVD. Importantly, the level of CVD 
risk in this group of RA patients in remission, as judged by 
these biomarkers, is comparable to that of community controls 
whereas patients with active RA had worse scores than con-
trols ( table 2 ). Furthermore, we found that a multivariate logistic 
regression model which included measures of endothelial dys-
function, arterial stiffness and AIx gave the best differentiation 
between patients with active RA and those with RA in remis-
sion. To our knowledge, this is the ﬁ rst study to examine CVD 
risk in patients in remission according to the CDAI criteria, and 
the ﬁ rst to compare levels of RHI between patients with RA and 
community controls. 
 In this study, systolic pressure in patients with active RA 
was an average of 8 mm Hg higher than patients in remission. 
Previous studies on brachial systolic pressure in patients with 
RA have given conﬂ icting results.  20–24  A recent interesting post 
hoc analysis of data from the BeSt trial showed that systolic 
pressure in patients with RA was correlated to disease activity 
and reduced by inﬂ iximab.  25  Our results further showed that 
patients with active RA had lower total cholesterol than patients 
with RA in remission and community controls, a ﬁ nding that 
has obvious implications for the validity of the calculation of the 
Framingham score and European Society of Cardiology SCORE 
in patients with active RA. Indeed, there were no statistically 
 Table 3  Comparison of cardiovascular risk markers across three patient categorisations† 
 Cohorts 
 Anti-CCP 
positive 
(n=55) 
 Anti-CCP 
negative 
(n=51)  p Value 
 Joint erosions 
>median (n=54) 
 Joint erosions 
median (n=53)  p Value 
 Extra-articular 
manifestations 
(n=13) 
 No extra-artarticular 
manifestations 
(n=100)  p Value 
Soluble biomarkers
 CRP (mg/l) 9.05 (1.71) 5.26 (1.82) 0.06 9.73 (2.12) 8.67 (2.05) 0.34 16.82 (3.45) 4.88 (0.98) <0.000*
 Total cholesterol (mmol/l) 5.20 (0.16) 5.47 (0.17) 0.22 5.12 (0.17) 5.60 (0.17) 0.03* 5.18 (0.31) 5.62 (0.09) 0.16
 HDL cholesterol (mmol/l) 1.66 (0.08) 1.60 (0.09) 0.55 1.59 (0.08) 1.67 (0.09) 0.46 1.69 (0.14) 1.65 (0.04) 0.79
 Atherogenic index 3.45 (0.15) 3.72 (0.16) 0.17 3.35 (0.17) 3.85 (0.16) 0.02* 3.34 (0.31) 3.68 (0.09) 0.27
 lnNT-proBNP (pmol/l) 2.43 (0.12) 2.27 (0.13) 0.30 2.49 (1.26) 2.15 (1.23) 0.03* 2.53 (0.26) 2.19 (0.08) 0.19
Peripheral biomarkers  
 RHI 2.13 (0.10) 2.28 (0.11) 0.30 2.06 (0.11) 2.30 (0.11) 0.08 2.05 (0.18) 2.17 (0. 0.44
  Brachial systolic 
pressure (mm Hg)
133 (2.4) 133 (2.4)  132 (2.6) 135 (2.5) 0.28 136 (4.8) 123 (1.3) 0.20
Central biomarkers  
 PWV 8.02 (0.19) 8.09 (0.21) 0.77 7.88 (0.22) 8.24 (0.20) 0.18 8.38 (0.35) 7.82 (0.10) 0.12
 AIx 22.84 (1.33) 22.55 (1.43) 0.87 23.86 (1.39) 22.98 (1.31) 0.61 23.17 (2.44) 19.74 (0.71) 0.17
  Central systolic 
pressure (mm Hg)
124 (2.5) 124 (2.7) 0.99 122 (2.7) 125 (2.5) 0.36 125 (4.7) 120 (1.4) 0.33
 IMT (mm) 0.74 (0.02) 0.75 (0.02) 0.74 0.75 (0.02) 0.76 (0.02) 0.55 0.73 (0.04) 0.74 (0.01) 0.66
Composite score  
 Framingham 9.99 (1.06) 9.54 (1.17) 0.78 10.96 (0.96) 12.29 (0.92) 0.26 8.58 (1.69) 10.54 (0.40) 0.25
 SCORE 3.42 (0.29) 9.3.23 (0.32) 0.64 3.77 (0.32) 3.21 (0.30) 0.15 2.60 (0.69) 2.98 (0.17) 0.59
 Estimated marginal mean (SE) presented with adjustments for age and sex. 
 *p<0.05. 
 †The following three categorisations were compared: anti-CCP positive vs negative; joint erosions >median vs ≤median joint erosions; and presence of extra-articular manifestations vs 
no extra-articular manifestations. 
 AIx, augmentation index; CRP, high sensitivity C reactive protein; Framingham, Framingham risk score; HDL cholesterol, high density lipoprotein; IMT, intima-median thickness; 
lnNT-proBNP, natural logarithm of N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RHI, reactive hyperemia index; SCORE, European Society of Cardiology SCORE risk 
calculator. 
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caused by wave reﬂ ection and have been shown to be superior 
to brachial pressure in predicting CVD.  38  AIx  42–44  and PWV  45    46  
are both reported to be increased in patients with high levels 
of inﬂ ammation. AIx has also been shown to be predicted by 
cumulative scores of disease activity,  43    44  whereas PWV—rather 
than AIx—is reduced by treatment with TNFα inhibitors.  45    47    48  
These heterogeneous ﬁ ndings may partly be explained by the 
peripheral vasodilation that accompanies acute inﬂ ammation, 
reducing pulse wave reﬂ ection and thereby the AIx and central 
systolic pressures.  49  
 NT-proBNP is an independent predictor of cardiovascular mor-
bidity and also general mortality in several populations including 
patients with RA.  50    51  NT-proBNP levels reﬂ ect the stretching of 
the atria and ventricles and are associated with measures of arte-
rial stiffness,  52  but this biomarker is also upregulated by proin-
ﬂ ammatory cytokines.  53  In patients with RA, NT-proBNP levels 
correlate with CRP and are reduced by TNFα inhibitors.  54    55  
 The IMT is a direct measure of the atherosclerotic disease 
process,  56  and an increased IMT predicts a greater risk of car-
diovascular events.  57  A recent meta-analysis of IMT in patients 
with RA included 25 studies of which 19 reported increased 
IMT in patients with RA, and it is thus surprising that our study 
did not ﬁ nd that patients with active RA had signiﬁ cantly higher 
IMT compared with the other groups.  58  
 We chose to categorise RA disease activity according to the 
CDAI criteria for active RA versus remission as it is a more 
stringent categorisation than the DAS criteria.  10  Since CRP 
is a marker of both RA disease activity and CVD risk, we 
found it advantageous to categorise patients by a composite 
score that does not include CRP as a component. Veriﬁ cation 
of RA disease remission by long-term radiographic outcome 
data would, however, have added validity to our ﬁ ndings. A 
weakness of our study is the low participation rate among the 
invited controls, which may challenge our ﬁ ndings through a 
selection bias. The controls participating in our study had a 
poorer CVD risk proﬁ le with regard to RHI and PWV com-
pared with patients in remission, which may suggest that some 
controls chose to participate as they felt the need for a CVD 
risk assessment. Such a bias would make a type I statistical 
error unlikely, but a type II error may have occurred. This is a 
cross-sectional study and our ﬁ ndings should be conﬁ rmed in a 
longitudinal study, preferably with incident CVD or mortality 
as the outcome. 
 This study indicates that classiﬁ cation of RA disease activity 
state according to the CDAI gives better differentiation between 
the groups than a comparison of CVD risk according to anti-CCP 
status, level of joint destruction or extra-articular manifestations 
( tables 2 and  3 ). Our results indicate that patients with active 
RA should receive extra attention from clinicians with regard to 
CVD prevention. 
 In conclusion, patients with active RA—but not those in 
remission—have signiﬁ cantly increased levels of biomarkers 
for CVD. These results support the association of inﬂ ammatory 
activity and markers of CVD risk in patients with RA and indi-
rectly support the ﬁ nding that remission in RA may also confer 
diminished cardiovascular morbidity. 
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ABSTRACT
Objectives Patients with rheumatoid arthritis (RA) 
have a higher mortality than the general population, and 
this increased mortality is related to demographic and 
disease variables. N-terminal pro-brain natriuretic peptide 
(NT-proBNP) is a predictor of mortality both in general 
and patient populations, but has not been shown to 
predict mortality in patients with RA. This study examines 
whether NT-proBNP can further improve the prediction of 
mortality in RA.
Methods 182 patients with RA of 5–9 years disease 
duration were comprehensively examined in 1997. 
Serum samples were frozen and later batch analysed 
for NT-proBNP levels and other biomarkers. Adjusted 
univariate and logistic regression analyses were 
performed with death within the 10-year follow-up period 
as the dependent variable. Signiﬁ cant predictors were 
also examined as dichotomised variables.
Results Mortality was predicted in univariate analyses 
by the following variables: age, sex, homozygosity for 
HLA-DRB1 shared epitope alleles, Health Assessment 
Questionnaire, 28-joint Disease Activity Score (DAS28) 
and NT-proBNP. A multivariate model with age, sex, 
DAS28 and NT-proBNP as independent variables showed 
the greatest discrimination.
Conclusion NT-proBNP provided incremental 
information in the prediction of mortality in this cohort of 
patients with RA.
INTRODUCTION
Mortality in patients with rheumatoid arthritis (RA) 
is increased compared with the general population 
by at least 50%.1–3 The excess mortality is largely 
due to cardiovascular disease (CVD), but malignan-
cies and infections are also increased.1 The abso-
lute risk of death from CVD is highest for elderly 
men with RA whereas the relative risk is highest 
for young women.4 Established predictors for all-
cause mortality in patients with RA are age, male 
sex, physical function, comorbidities and rheuma-
toid factor (RF).1 5 A homozygote shared epitope 
(SE) genotype has been found to be associated 
with premature death, and speciﬁ cally death from 
ischaemic heart disease.6–8 Inﬂ ammatory markers 
such as C reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) have also been shown to 
be important risk indicators in RA, pertaining to 
general mortality, CVD mortality and cardiovascu-
lar events.9 10
The level of N-terminal pro-brain natriuretic 
peptide (NT-proBNP) predicts all-cause and cardiac 
mortality in the general population, as well as in 
cohorts of patients with heart failure and stable 
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coronary heart disease.11–14 NT-proBNP has been 
found to be increased in patients with RA and 
is cross-sectionally associated with the level of 
inﬂ ammation.15 16 As far as we know, NT-proBNP 
has not been investigated as a predictor of mortal-
ity in patients with RA.
Our hypothesis was that NT-proBNP is an inde-
pendent predictor of 10-year mortality in patients 
with RA. We have thus examined the incremental 
value of NT-proBNP in the prediction of mortality 
in RA across a panel of established and potentially 
novel risk factors.
MATERIAL AND METHODS
Patient cohort
One hundred and eighty-two patients with RA par-
ticipated in the 5-year follow-up of the EURIDISS 
study in 1997. Data from this comprehensive visit 
are used as the baseline for the analyses in this 
paper.17 The patients were diagnosed according to 
the 1987 American College of Rheumatology cri-
teria.18 The mean age at baseline was 55.7 years 
(range 27.3–74.7), mean disease duration was 7.1 
years (range 4.76–9.4) and 134 (74%) were women. 
Eighteen patients (17%) reported previous CVD. 
At the 10-year follow-up in 2007, 31 (17%) of the 
patients had died.
Baseline variables 1997
A questionnaire recording data on demographics, 
comorbidities and health status was completed 
by patients in collaboration with the study nurse. 
Health status was measured by the Stanford Health 
Assessment Questionnaire (HAQ), a multidimen-
sional questionnaire that captures patient function-
ing in several areas of daily life,19 and by the generic 
Nottingham Health Proﬁ le (NHP).20 A checklist 
modiﬁ ed from Arthritis Impact Measurement 
Scales was used to assess the presence of 16 possible 
comorbidities including patient self-reported pres-
ence of hypertension, angina, myocardial infarc-
tion or other cardiac diseases and diabetes, without 
any diagnostic speciﬁ cations.21 The trained study 
nurse also performed a clinical examination for 
the presence of nodules and joint swelling and the 
composite Disease Activity Score was calculated 
(DAS28 consisting of tender joint score, swollen 
joint score, ESR and patient visual analogue scale 
for global assessment).22 Biomarkers were exam-
ined from blood (DNA) and serum samples that 
had been frozen at −70°C: anti-cyclic citrullinated 
antibody (anti-CCP) by ELISA (Inova Diagnostics, 
San Diego, California, USA), high sensitivity CRP 
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by phyCardioPhase, nefelometry (Dade Behring, Deerﬁ eld, 
Illinois, USA) and RF IgM using the in-house ELISA method.
NT-proBNP was measured using a Modular E170 device 
(Roche Diagnostics, Mannheim, Germany). The coefﬁ cient of 
variation on batch analyses was 1.4%. DRB1 sequencing was 
performed using BigDye Terminator V3.1 chemistry (Applied 
Biosystems, Foster City, California, USA) on an ABI 3730 DNA 
Analyzer (Applied Biosystems) followed by allele assignment 
(AssignSBT V.3.2.7; Conexio Genomics, Applecross, Australia). 
SE was deﬁ ned as the following alleles: 0101, 0102, 0401, 0404, 
0405, 0408, 1001 and 1402.
Haemoglobin and ESR were analysed at the time of 
examination.
Outcome measures
The patients were registered as dead at the 2007 follow-up 
study on the basis of information from the Norwegian National 
Population Register.
Statistical analyses
Baseline demographic disease activity, comorbidities, health 
status variables and levels of soluble biomarkers were com-
pared between patients who had died at the 10-year fol-
low-up and the survivors using the χ2 test, Student t test or 
Mann–Whitney U test as appropriate. Two-tailed p values are 
reported.
The associations between baseline variables and 10-year 
mortality were examined in a logistic regression procedure that 
was adjusted for age and sex. Variables that were signiﬁ cantly 
skewed were transformed into the natural logarithm (CRP, ESR, 
NT-proBNP) or dichotomised at the median (NHP and HAQ). 
Anti-CCP and IgMRF levels were classiﬁ ed as elevated if ≥25 U/
ml. Separate models were constructed for associated variables. 
Finally, a multivariate stepwise backward regression model was 
constructed that initially included all variables that were sig-
niﬁ cant at the p≤0.15 level. The validity of the ﬁ nal model was 
conﬁ rmed by performing sensitivity analyses with NT-proBNP 
dichotomised according to the age and sex-speciﬁ ed 95th per-
centile in healthy blood donors,23 and by forcing baseline CRP 
and history of CVD into the model. Previously excluded vari-
ables of baseline disease activity were also re-entered into the 
ﬁ nal model to check for possible confounding. To verify that 
the models were not overﬁ tted, variables that were signiﬁ cant 
predictors of mortality in the separate models were dichoto-
mised at the median and, for each predictor, a sum variable was 
constructed that also included age and sex (eg, age > median =1 
+ female sex =1 + HAQ ≤ median = 0). NT-proBNP was then 
added to the logistic models that included one such sum vari-
able and improved prediction was assessed by examining the 
CI of the receiver operating characteristics (ROC) curves. The 
relationship between NT-proBNP and mortality was addition-
ally explored using fractional polynomial analysis in STATA. 
In addition, we checked for model lack of ﬁ t by applying the 
Hosmer–Lemeshow goodness-of-ﬁ t test to the ﬁ nal model 
and, ﬁ nally, we plotted Cook’s distances and repeated the ﬁ nal 
step of the analyses after the removal of outliers. When not 
 otherwise mentioned, the analyses were performed using SPSS 
Version 14.
RESULTS
Of the 182 patients, 31 had died during the 10-year follow-up 
period. Details of missing data are given in table 1. Complete 
baseline data for variables included in the ﬁ nal model were 
available for 117 patients, 21 of whom had died during the 
10-year follow-up period. These patients were similar to the 
main cohort with regard to age and level of IgM RF, anti-CCP, 
HAQ and DAS28, but fewer women had participated in the 
complete data collection (complete data were available for 
76.6% of men vs 60.0% of women, p=0.04).
Bivariate analyses
As expected, the patients who had died were older, more often 
male, had a higher frequency of CVD-related comorbidities and 
poorer functional status (HAQ and NHP) at baseline. They also 
had higher baseline levels of DAS28, and NT-proBNP, CRP and 
ESR levels were borderline signiﬁ cantly increased in patients 
who died (p=0.08 and p=0.06, respectively; table 1).
Logistic regression
Signiﬁ cant and borderline predictors of 10-year mortality are 
shown in table 2. In the demographic model, homozygous SE 
adjusted for age and sex correctly predicted 8 of 29 deaths. 
Level of education was not a signiﬁ cant predictor of mortality 
(OR 0.90, 95% CI 0.32 to 2.49). Among the variables of disease 
 activity, only DAS28 was a signiﬁ cant predictor with a predic-
tion of 10 of 30 deaths. The rejected variables were nodules (OR 
1.20, 95% CI 0.39 to 3.65), anti-CCP (OR 1.60, 95% CI 0.54 to 
4.77) and IgM RF (OR 0.85, 95% CI 0.30 to 2.37).
None of the comorbidities were signiﬁ cant predictors at 
p≤0.05, although a history of myocardial infarction approached 
this level. Neither hypertension (OR 1.32, 95% CI 0.45 to 3.85) 
nor diabetes (OR 1.11, 95% CI 0.26 to 4.77) contributed to the 
model. The dichotomised variables reﬂ ecting health status (NHP 
and HAQ) were both signiﬁ cant in the adjusted analysis, but 
NHP was surpassed by HAQ in a multivariate ‘health status 
model’ and lost signiﬁ cance. A high NHP score adjusted for age 
Table 1 Comparison of baseline variables between patients who 
were dead (n=31) and those who were alive (n=151) after 10 years of 
follow-up
Baseline variables (1997) Deceased by 2007 Alive in 2007 p Value
Demographic variables (n=182)
 Age 62.0 (0.9) 48.4 (1.0) <0.001
 Female sex 19 (59.4) 120 (76.9) 0.04
 Education high vs low 8 (25.0) 50 (32.1) 0.43
RA disease variables
 DAS28 (n=172) 5.0 (0.3) 3.87 (0.12) <0.001
 Presence of nodules (n=181) 6 (19.4) 22 (14.9) 0.53
Comorbidities (n=178)
 Hypertension 8 (25.8) 13 (8.7) 0.01
 MI 9 (30.0) 9 (6.1) <0.001
 Diabetes 3 (9.7) 11 (7.4) 0.67
Health status
 HAQ (n=179) 1.3 (0.1) 0.8 (0.1) <0.001
 NHP total (n=176) 2.0 (0.1) 1.5 (0.1) <0.001
Biomarkers
 SE homozygote (n=168) 12 (40.0) 35 (24.3) 0.08
 CRP (n=127) 13.5 (16.4) 8.6 (10.4) 0.08
 ESR (n=177) 25.8 (3.7) 18.2 (1.2) 0.06
 NT-proBNP (n=124) 61.0 (79.8) 11.2 (8.7) <0.001
 Haemoglobin (n=177) 13.7 (0.3) 14.5 (0.1) 0.54
 Anti-CCP level (n=127) 140 (23) 118 (11) 0.42
 IgMRF level (n=127) 95 (23) 71 (9) 0.41
Mean (SE) for continuous variables, numbers (%) for categorical variables.
anti-CCP, anti-cyclic citrullinated peptide antibody; CRP, high sensitivity C reactive 
protein; DAS28, Disease Activity Score for 28 joints; ESR, erythrocyte sedimentation 
rate; HAQ, Stanford Health Assessment Questionnaire; IgMRF, rheumatoid factor 
IgMRF; MI, myocardial infarction; NHP, Nottingham Health Proﬁ le; NT-proBNP, 
N-terminal pro-brain natriuretic peptide; SE, shared epitope.
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Biomarkers are quantiﬁ able biological parameters that serve 
as important indices of healthy or pathological processes.24 
Biomarkers reﬂ ecting RA disease activity can be grouped into 
two clusters, the variables in each cluster being mutually closely 
correlated. One cluster includes variables that describe patient-
centred outcomes; these may be derived from patient self-re-
ported questionnaires of which the HAQ score is an example. 
The other cluster includes measures of RA disease-centred out-
comes such as ESR, CRP, RF and radiographic joint erosions. In 
general, patient-centred outcomes are reported to be better pre-
dictors of mortality than disease-centred variables1 although, to 
our knowledge, they have not previously been compared with 
SE or NT-proBNP. NT-proBNP as a single variable (adjusted for 
age and sex) had approximately the same predictive ability as 
the HAQ score. The ﬁ nal model that included DAS28 was supe-
rior to other models, although the CIs of the ROC curves were 
not signiﬁ cantly different.
and sex predicted 7 of 27 deaths (OR 3.22, 95% CI 1.18 to 8.80) 
whereas a higher HAQ score predicted 16 of 30.
NT-proBNP was found to be an independent predictor in 
the ‘biomarker model’ predicting 12 of 23 deaths. LnCRP was 
also a near-signiﬁ cant predictor of death in the age and sex-
adjusted model (OR 1.48, 95% CI 0.95 to 2.31) but did not 
perform when NT-proBNP was included in the model. LnESR 
(OR 1.42, 95% CI 0.80 to 2.51) did not carry signiﬁ cance in 
the model.
The ﬁ nal model included DAS28 and NT-proBNP and predicted 
14 of 21 deaths. The positive predictive value of the model was 
74% and the negative predictive value was 93%. The ROC curves 
comparing the ﬁ nal model with the health status model showed 
that the combination of DAS28 and NT-proBNP had the greatest 
area under the curve (AUC), although the CIs were  overlapping 
and the difference was thus not signiﬁ cant (ﬁ gure 1).
The sensitivity analyses supported the main results. 
NT-proBNP categorised according to the age and sex-speciﬁ c 
95th percentile provided by the manufacturer in package 
inserts (based on samples from 2264 blood donors and patients 
aged between 18 and 65 and free from CVD)23 was a slightly 
poorer predictor of death than the continuous variable (sensi-
tivity 62%, speciﬁ city 95%, accuracy 89%). The ﬁ nal model 
was not signiﬁ cantly altered by forcibly re-entering previously 
rejected variables (including self-reported CVD and hyperten-
sion), and no other variables were found to be signiﬁ cant pre-
dictors of the outcome nor to be confounders of the included 
variables. Consecutive models that each included one sum vari-
able showed that NT-proBNP remained a signiﬁ cant predictor of 
mortality and contributed signiﬁ cantly to each model (data not 
shown). According to the fractional polynomial analyses, the 
relationship between NT-proBNP and death was best described 
by a linear equation. The model exhibited no evidence of lack 
of ﬁ t (Hosmer–Lemeshow, p=0.46) and was not substantially 
changed after the removal of three outliers.
DISCUSSION
Our results show that NT-proBNP is an independent predictor 
of 10-year mortality in this cohort of patients with longstand-
ing RA. Established risk factors for RA mortality were also sig-
niﬁ cant predictors in our cohort and the HAQ score, adjusted 
for age and sex, had the highest single variable discriminatory 
power.
Table 2 Logistic regression models for the prediction of death during 10-year follow-up (OR (CI) and p value)
 
Demographic 
model (n=168)
Disease activity 
model (n=172)
Comorbidities 
model (n=178)
Health status 
model (n=178)
Biomarker 
model (n=124)
Final 
model (n=117)
Age 1.16 (1.08 to 1.24)
p<0.001
1.15 (1.07 to 1.23)
p<0.001
1.14 (1.07 to 1.23)
p<0.001
1.16 (1.08 to 1.25)
p<0.001
1.01 (1.01 to 1.21)
p=0.02
1.16 (1.08 to 1.24)
p<0.001
Female sex 0.56 (0.20 to 1.51)
p=0.25
0.43 (0.16 to 1.14)
p=0.09
0.58 (0.23 to 1.51)
p=0.27
0.47 (0.18 to 1.27)
p=0.14
0.46 (0.14 to 1.49)
p=0.20
0.46 (0.13 to 1.67)
p=0.27
SE homozygote 3.01 (1.09 to 8.36)
p=0.03
DAS28 1.57 (1.11 to 2.22)
p=0.01
1.67 (1.06 to 2.65)
p=0.03
Previous MI 2.59 (0.81 to 8.27)
p=0.11
HAQ 4.88 (1.78 to 13.43)
p=0.002
LnNT-ProBNP 26.85 (3.56 to 202.40)
p=0.001
24.23 (2.85 to 206.02)
p=0.004
Accuracy 85.1 84.9 87.1 89.3 88.1 89.7
Sensitivity 27.6 33.3 36.7 53.3 52.2 66.7
Speciﬁ city 97.1 95.8 97.3 96.6 96.1 94.8
DAS28, Disease Activity Score for 28 joints; HAQ, Stanford Health Assessment Questionnaire; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SE, shared 
epitope.
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Figure 1 Receiver operating characteristics (ROC) curves comparing 
the performance of two models predicting mortality after 10 years. 
Models adjusted for age and sex. Area under the curve for N-terminal 
pro-brain natriuretic peptide (NT-proBNP) and Disease Activity Score 
(DAS) model 0.91, for Stanford Health Assessment Questionnaire (HAQ) 
model 0.85.
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NT-proBNP is a validated marker of heart failure that has been 
shown to complement traditional risk factors as an indepen-
dent predictor of all-cause mortality in a community cohort.25 
This biomarker is the biologically inactive N-terminal fragment 
of the active hormone BNP and is part of a family of natriuretic 
peptides that cause vasodilation, natriuresis and smooth muscle 
modulation in response to myocardial stretch.26 NT-proBNP 
and BNP release may also be upregulated by proinﬂ ammatory 
cytokines.27 It is thus possible that measures of inﬂ amma-
tion or RA disease activity could attenuate the link between 
NT-proBNP and mortality. In the failing heart, NT-proBNP lev-
els can accordingly be reduced by medication that improves 
cardiac function28 and, interestingly, a recently published paper 
found that NT-proBNP is also reduced in patients with RA by 
treatment with a tumour necrosis factor α inhibitor.29 In our 
ﬁ nal model, NT-proBNP was maintained as a signiﬁ cant predic-
tor of mortality when self-reported CVD, self-reported hyper-
tension and current inﬂ ammation were forcibly imputed into 
the model.
The observed yearly all-cause mortality in this cohort was 
1.7%. A 4% yearly mortality has been observed in another 
Norwegian study on data collected from 1977 to 1992, two 
decades prior to our inclusion date.3 Our observed yearly 
mortality was also lower than the 2.4–2.5% observed in the 
Minnesota cohort, although our data are within the CIs of the 
Minnesota ﬁ ndings.30 The average age in these cohorts seems 
comparable, and we believe that the lower mortality observed 
in our study might be explained by the more recent data col-
lection, mirroring the reduced mortality seen in the general 
population. The EURIDISS study is an inception cohort that 
speciﬁ cally included patients with >5 and <10 years of disease 
duration and, as death in RA has been found to be increased 
early in the disease course, this may have biased our results 
towards a lower mortality.31
One strength of our study is the prospective longitudinal 
design with subsequent batch analyses of baseline soluble bio-
markers. The results of this study conﬁ rm several previous ﬁ nd-
ings concerning predictors of mortality in RA, providing validity 
to our ﬁ ndings. The main weakness of this study is the sam-
ple size which may lead to a type II statistical error regarding 
less powerful predictors. Hypertension and presence of diabe-
tes were not signiﬁ cant predictors of mortality in our models, 
and this may well be due to the low number of patients with 
these conditions. We chose to use the 1997 examination as the 
baseline as information on CVD had been collected at this time 
point. However, we do not have details of ventricular function, 
renal function, lipid levels or smoking habits from this visit, all 
of which are possible predictors and confounders. Ideally we 
should have entered NT-proBNP into multivariate models that 
already included composite and extensively validated scores, 
such as the Framingham score, in order to discern whether 
NT-proBNP can further improve prediction of mortality in addi-
tion to these widely used predictors. Lack of knowledge about 
the cause of death prohibited subgroup analyses but, because 
of the limited number of patients, the cohort would not have 
been eligible for robust subgroup analyses according to cause 
of death.
In summary, NT-proBNP compared favourably with the 
established predictors of mortality in this cohort of patients 
with RA. The resultant model gave an improved sensitivity, 
speciﬁ city and the highest AUC of the ROC analysis. Additional 
studies are encouraged to replicate and further explore the value 
of NT-proBNP as a prognostic biomarker in RA.
Acknowledgements The authors thank Benedicte Lie and Siri T Flåm for genotyping 
the patients with regard to HLA-DRB1 and Petter Mowinckel for providing statistical 
expertise. They also thank Roche Diagnostics, Mannheim, Germany for providing the 
kits for NT-proBNP testing (Dr B Trauth).
Funding This study was supported by grants from the Eastern Norway Regional 
Health Authority. The data collection in EURIDISS was supported by The Research 
Council of Norway, The Norwegian Rheumatism Association, The Norwegian Women 
Public Health Association, the Grethe Harbitz Legacy and the Marie and Else Mustad’s 
Legacy.
Competing interests None.
Ethics approval The project was approved by the Norwegian Regional Committee 
for Research Ethics.
Patient approval Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
 1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp 
Rheumatol 2008;26(5 Suppl 51):S35–61.
 2. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among 
patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General 
Practice Research Database. J Rheumatol 2003;30:1196–202.
 3. Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients 
with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 
2000;29:29–37.
 4. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in 
rheumatoid arthritis. Ann Rheum Dis 2006;65:1608–12.
 5. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin 
Exp Rheumatol 2009;27(4 Suppl 55):S127–30.
 6. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 
and persistent chronic inﬂ ammation contribute to cardiovascular events and 
cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 
2007;57:125–32.
 7. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 
gene with premature death, particularly from cardiovascular disease, in patients 
with rheumatoid arthritis and inﬂ ammatory polyarthritis. Arthritis Rheum 
2008;58:359–69.
 8. Mattey DL, Thomson W, Ollier WE, et al. Association of DRB1 shared epitope 
genotypes with early mortality in rheumatoid arthritis: results of eighteen 
years of followup from the early rheumatoid arthritis study. Arthritis Rheum 
2007;56:1408–16.
 9. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein 
and prediction of death from cardiovascular disease in patients with inﬂ ammatory 
polyarthritis: a ten-year followup study of a primary care-based inception cohort. 
Arthritis Rheum 2005;52:2293–9.
10. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Raised erythrocyte sedimentation 
rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 
2007;66:76–80.
11. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and 
ischemia in patients with stable coronary disease: data from the Heart and Soul study. 
Circulation 2003;108:2987–92.
12. Kragelund C, Grønning B, Køber L, et al. N-terminal pro-B-type natriuretic peptide and 
long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666–75.
13. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of 
cardiovascular events and death. N Engl J Med 2004;350:655–63.
14. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide 
predicts outcome after hospital discharge in heart failure patients. Circulation 
2004;110:2168–74.
15. Solus J, Chung CP, Oeser A, et al. Amino-terminal fragment of the prohormone 
brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 
2008;58:2662–9.
16. Provan SA, Angel K, Odegård S, et al. The association between disease activity and 
NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. 
Arthritis Res Ther 2008;10:R70.
17. Uhlig T, Smedstad LM, Vaglum P, et al. The course of rheumatoid arthritis and 
predictors of psychological, physical and radiographic outcome after 5 years of 
follow-up. Rheumatology (Oxford) 2000;39:732–41.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 
1987 revised criteria for the classiﬁ cation of rheumatoid arthritis. Arthritis Rheum 
1988;31:315–24.
19. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. 
Arthritis Rheum 1980;23:137–45.
20. Houssien DA, McKenna SP, Scott DL. The Nottingham Health Proﬁ le as a 
measure of disease activity and outcome in rheumatoid arthritis. Br J Rheumatol 
1997;36:69–73.
10_annrheumdis127704.indd   1949 9/30/2010   3:56:39 PM
Extended report
Ann Rheum Dis 2010;69:1946–1950. doi:10.1136/ard.2009.1277041950
21. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The 
arthritis impact measurement scales. Arthritis Rheum 1980;23:146–52.
22. Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modiﬁ ed disease activity scores that 
include twenty-eight-joint counts. Development and validation in a prospective 
longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 
1995;38:44–8.
23. Hess G, Runkel S, Zdunek D, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) 
in healthy blood donors and in patients from general practitioners with and without a 
diagnosis of cardiac disease. Clin Lab 2005;51:167–72.
24. Lassere MN, Johnson KR, Boers M, et al. Deﬁ nitions and validation criteria for 
biomarkers and surrogate endpoints: development and testing of a quantitative 
hierarchical levels of evidence schema. J Rheumatol 2007;34:607–15.
25. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of ﬁ rst 
major cardiovascular events and death. N Engl J Med 2006;355:2631–9.
26. Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. 
Heart Fail Clin 2009;5:471–87.
27. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic 
peptide at the transcriptional and translational levels by pro-inﬂ ammatory cytokines 
and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP 
kinase. J Mol Cell Cardiol 2004;36:505–13.
28. O’Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be 
guided by BNP levels? Nat Rev Cardiol 2010;7:13–20.
29. Peters MJ, Welsh P, McInnes IB, et al. TNF{alpha} blockade therapy reduces 
circulating NT-proBNP levels in RA patients with active disease: results from a 
prospective cohort study. Ann Rheum Dis 2010 Apr 7 [Epub ahead of print]. 
30. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap 
between rheumatoid arthritis patients and the general population. Arthritis Rheum 
2007;56:3583–7.
31. Young A, Koduri G, Batley M, et al.; Early Rheumatoid Arthritis Study (ERAS) 
group. Mortality in rheumatoid arthritis. Increased in the early course of disease, 
in ischaemic heart disease and in pulmonary ﬁ brosis. Rheumatology (Oxford) 
2007;46:350–7.
10_annrheumdis127704.indd   1950 9/30/2010   3:56:39 PM

